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Abstract
Inadequately controlled acute pain is a problem for hospitalized patients. Non-pharmacological
pain management interventions (NPPMIs) are recommended but underutilized. Nurse-directed
lavender aromatherapy is a feasible and effective NPPMI. Patients at a community hospital,
including its surgical-orthopedic unit, reported lower patient pain management experience scores
than the average score of Magnet Recognition status hospitals. The community hospital planned
to improve pain management by implementing nurse-directed lavender aromatherapy. The
purpose of this evidence-based practice project was to fortify the hospital’s nurse-directed
lavender aromatherapy implementation with change agents. A logic model guided
implementation. Project aims were to increase the surgical-orthopedic unit’s pain management
experience scores and to offer nurse-directed lavender aromatherapy to all appropriate patients
by close of the project. Change agents included a Doctor of Nursing Practice student and nurse
pain champions. Interventions included Doctor of Nursing Practice student-led: (a) surgicalorthopedic unit Lunch & Learn presentations and Rounding for Results sessions and (b)
implementation discussions with nurse pain champions from four units, including the surgicalorthopedic unit. Because of these interventions, surgical-orthopedic unit patient pain experience
scores increased from 43rd percentile to 78th percentile. In five of six project weeks, all
appropriate surgical-orthopedic unit patients were offered nurse-directed lavender aromatherapy.
Adoption of the practice change was successful, but slower than anticipated because of slow
adoption by the nurses. Nurse leaders responded to this slow adoption by adding additional
change agent rounds. Logic model development and change agents are effective strategies for
NPPMI implementation.
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Change Agent Impact on Pain Management Experience through Lavender Aromatherapy:
Evidence-Based Practice Project
Introduction
Patients experiencing acute pain, particularly post-operative pain, often report it is
inadequately controlled (Chou et al., 2016). Provision of non-pharmacological pain management
interventions (NPPMIs) is a recommendation in evidence-based clinical practice guidelines
(CPGs) (Chou et al., 2016; Mack et al., 2014; Registered Nurses’ Association of Ontario
[RNAO], 2013). A recent Joint Commission notice advised that NPPMIs are a critical element
for effective pain management (Joint Commission, 2018). Aromatherapy with direct lavender
inhalation has been associated with patient report of decrease in pain intensity in patients with
acute and chronic pain, particularly post-operative pain (Bagheri-Nesami, Espahbodi, Nikkhah,
Shorofi, & Charati, 2014; Heidari Gorji et al., 2015; Irmak Sapmaz et al., 2015; Johnson et al.,
2016; Karaman et al., 2016; Kim et al., 2007; Lakhan, Sheafer, & Tepper, 2016).
Clinical aromatherapy is the topical application or inhalation of an essential oil to assist
patients in managing symptoms such as pain, nausea, or anxiety (Buckle, 2015). Aromatic oils
were used in ancient China, Egypt, India, and Greece, where the physician Hippocrates
advocated aromatic baths and massages (Alliance of International Aromatherapists, n.d.). The
term aromatherapy was created in 1937 by a chemist in France, René-Maurice Gattefossé
(Buckle, 2015). In that same time-period, nurse and biochemist Marguerite Maury provided
community education about the use aromatherapy to enhance wellness (Buckle, 2015).
Interventions such as aromatherapy require implementation science approaches, such as
the Iowa model of evidence-based practice (EBP), to optimize adoption and sustainment (Cullen
& Adams, 2012). Change agents are identified as an implementation strategy in the Iowa model
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including unit-based champions, local opinion leaders, and external experts (Cullen et al., 2018).
The purpose of this EBP project was to employ internal and external change agents to fortify
implementation of lavender aromatherapy to improve patient pain management experience in a
community hospital. The change agents for this project included a Doctor of Nursing Practice
(DNP) student and four unit-based nurse pain champions (PCs).
Background and Significance
Needs Assessment
The 216-bed community hospital for this study resided in a 10-hospital system in the
Mid-Atlantic United States. This community hospital resides in a suburban region near a major
East Coast city and became a member of the health system in December 2012 ("Hospital
merger," 2012).
Pain management for patients has been a focus for this health system since fiscal year
(FY) 2014, when it endorsed the Assessment and Management of Acute Pain in the Hospitalized
Adult Nursing CPG (2014) as the standard of practice (Mack et al., 2014). This CPG was
adapted from a guideline developed by the Registered Nurses Association of Ontario (2013) in
consultation with a nationally known nurse pain expert. The recommendations pertinent to
NPPMIs are:
•

“Psychological (psychosocial) interventions such as cognitive behavior therapy,
music, distraction, relaxation techniques, and education should be considered in pain
management because these interventions affect the way a person thinks, feels, and
responds to pain” (Mack et al., 2014, p. 10).

•

“Physical interventions such as physiotherapy and exercise, massage, positioning, and
application of heat or cold should be considered along with pharmacological
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interventions to reduce pain, improve sleep, mood and general wellbeing. When using
more specialized interventions (TENS, acupuncture) consult the appropriate
interprofessional team” (Mack et al., 2014, p. 10).
•

“Evaluate any non-pharmacological (physical and psychological) interventions for
effectiveness and the potential for interactions with pharmacological interventions
(Ib)” (Mack et al., 2014, p. 10).

•

“Reassess the person’s response to the pain management interventions consistently
using the same re-evaluation tool…The intensity of monitoring (frequency and
duration) depends on a person’s risk profile for opioid-induced sedation and
respiration depression and the onset and duration of action or potential adverse effects
of the pharmacologic and non-pharmacologic interventions” (Mack et al., 2014, p.
10-11).

In FY 2016, key pain management stakeholders from the health system endorsed the
recommendations in the American Pain Society postoperative pain management CPG (Chou et
al., 2016). The authors recommended NPPMIs such as transcutaneous electrical nerve
stimulation (TENs) and cognitive-behavioral therapies, including relaxation therapies.
Aromatherapy is an intervention that promotes relaxation in patients with pain but is not
specifically included in the list of relaxation therapies in either CPG (Czarnecki & Turner, 2018).
In September 2016, the health system’s Nursing Practice Council (NPC) completed an
audit of 65 open medical records from 10 hospitals to evaluate documentation of delivery of key
recommendations in the Assessment and Management of Acute Pain in the Hospitalized Adult
Nursing CPG (Mack et al., 2014). The audit included an assessment of the documentation of
presence and type of NPPMIs provided to patients not achieving an acceptable pain goal. In the
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audited patients, less than 32% of those with unmet pain goals had received a NPPMI (Appendix
A). A total of 21 NPPMIs were documented; some patient records recorded more than one
intervention. Of the 21 NPPMIs noted, repositioning was documented in nine records,
application of cold was documented in two records, and provision of quiet environment was
documented in two records. Application of heat, assistance with activities of daily living,
comfort measures, distraction, education, relaxation, pressure relief, reduced stimuli, and
relaxation techniques were each documented in one record. The NPC advised that additional
NPPMIs for patients were needed and should be selected based on efficacy and feasibility for
nursing practice.
The need for additional NPPMIs was validated by observations on bedside pain CPG
rounds at each of the 10 hospitals in the health system by the advanced practice registered nurse
(APRN) responsible for oversight of the CPG. Two nurses with expertise in pain management
from outside of the health system were consulted regarding potential NPPMIs. These nurses
identified aromatherapy as a feasible and effective intervention for clinical nurses to provide to
hospitalized patients to help manage pain (D. Chapa, personal communication, September 8,
2016; T. Dintzner, personal communication, September 23, 2016). Subsequently, a systematic
review of lavender aromatherapy for acute pain management in adults, defined as those ages 18
and older, was completed in December 2016 by the APRN (Mack & Zhou, 2016). Lavender
essential oil was selected because it was: (a) the most frequently identified effective essential oil
used in the acute pain randomized controlled trials identified in the systematic review and (b)
one of the most effective scents identified in an aromatherapy observational study at a mid-west
health system (Mack & Zhou, 2016; Johnson et al., 2016). In February 2017, the nurse pain
expert consulted in 2014 returned to the health system to provide educational sessions and
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hospital site visits to evaluate the CPG implementation (Gordon, 2017). Based on observations
during these site visits, the nurse pain expert validated the need to increase the NPPMI options
for nurses to provide to patients.
In August 2017, an advisory team of the health system’s Nursing Leadership
Development Program presented a system-level plan to fully implement the Assessment and
Management of Acute Pain in the Hospitalized Adult Nursing CPG. Implementation of
aromatherapy for pain management was among the recommendations in the plan.
In October 2017, the health system APRN attended the “How to Launch an
Aromatherapy Program within a Hospital or Health System” course presented by the Penny
George Institute for Health and Healing at Allina Health in Minnesota to develop a nursedirected lavender aromatherapy pain management protocol and system implementation plan
(Streeter, 2017). In November 2017, the health system held a Pain Summit at which a clinical
nurse presented education about aromatherapy for pain management (Ryan, 2017).
Development of a product trial of lavender aromatherapy for pain management and associated
deliverables was begun in December 2017 and completed in August 2018 (Appendix B). Project
plan steps included:
•

Obtaining approval for the product by Nursing Product Evaluation and Standardization
Council (NPESC) in collaboration with the health system supply chain team. NPESC
required a product trial, including clinical nurses’ evaluation of the lavender inhalers,
prior to final approval for patient use in all hospitals in the health system. In January
2018, the supply chain team located several lavender aromatherapy products to evaluate
that met safety criteria described by the Penny George Institute aromatherapist (Streeter,
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2017). The NPESC approved one of the lavender products that was an inhaler for the
trial.
•

Development of a clinical protocol (Appendix C). The clinical protocol was vetted with
health system physician subject matter experts: an allergist, a pulmonologist specializing
in asthma management, and an anesthesiologist. Additional input included health system
leaders from occupational health (which manages the health of employees) and laundry
services (which could be impacted by aromatherapy products being inadvertently mixed
with the linens) who jointly advised that the lavender inhaler was an acceptable product.

•

Creation of a patient and family education lavender aromatherapy document by the NPC
with consultation by a health literacy expert and endorsed by the Patient and Family
Education Council (Appendix D).

•

Development of nursing education on lavender aromatherapy for the product trial and
endorsement for system-wide use after the trial by the Nursing Professional Development
Excellence Committee (Appendices E and F).

•

Development of nursing documentation for the nurse-directed aromatherapy protocol
within the electronic medical records (EMR) system that is used in nine of the 10 health
system hospitals. This included: (a) a clinical decision support process to assist nurses to
determine the appropriateness of lavender aromatherapy, (b) prompts to document pain
intensity after the first administration, and (c) fields for documentation of initial and
ongoing inhaler use (see screenshots in Appendix E).

•

Development of a physician communication brief highlighting key research that was
vetted with physician leaders at the pilot hospitals and disseminated as part of the pilot
(Appendix G).

CHANGE AGENT IMPACT ON PAIN THROUGH AROMATHERAPY

12

The pilot was completed at two hospitals in August 2018 and resulted in the NPESC
endorsement of the lavender Aethereo®Sticks inhaler product for system-wide implementation in
September 2018. No adverse events were noted in patients, visitors, nurses, physicians, or other
hospital associates during the trial. The community hospital for this study was not a pilot site. A
launch brief containing product cost and ordering information was issued by the system supply
chain team in November 2018 (Appendix H).
Among the 10 hospitals in the health system, the study community hospital was selected
as the focus for this project, because it had not met the health system pain management patient
experience target score of the Magnet hospital average in over 12 months. The community
hospital scored at the 33rd percentile in the prior 12 months. In the first quarter of fiscal year
2019, the community hospital scored in the 31st percentile as compared to NRC database Magnet
hospitals. The NRC database analysis indicated pain management was one of the key drivers of
patients’ overall rating of the community hospital on a zero to 10 scale. The surgical-orthopedic
unit scores were in the lower half of study hospital’s units’ scores, scoring at the 30th percentile
over the prior 12 months and in the 12th percentile for the first quarter of FY 2019.
Annual observational visits beginning in 2016 conducted by the health system’s APRN
responsible for pain management and the nurse pain expert visit in 2017 validated the
community hospital’s patients were not receiving cognitive NPPMIs. Due to the need for
cognitive NPPMI to improve patients’ pain management experience, implementation of nursedirected lavender aromatherapy was an organizational priority supported by the community
hospital’s Chief Nursing Officer (CNO) and Vice-President for Medical Affairs.
Each hospital in the health system, including the community hospital for this study,
convened a multidisciplinary committee, including the hospital supply chain team, to implement
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the aromatherapy protocol with lavender inhalers. The community hospital’s plan was impacted
by the transition to the health system’s EMR system on November 29, 2018. This EMR system
included the documentation fields and decision support necessary for implementation of
aromatherapy. To allow clinicians time to adapt to the new system, the community hospital’s
implementation team determined aromatherapy implementation would commence in the first
quarter of FY 2019.
During this time-period, a system-wide nurse PC program began on October 31, 2018
with training for groups of nurse leaders and clinical nurses from all 10 hospitals. Clinical
nurses from all inpatient units were appointed by nurse leaders to be nurse PCs. The program
required each nurse PC to attend at least 75% of monthly meetings. The community hospital
held its first PC meeting in the first quarter of FY 2019, on January 23, 2019.
In addition to the aromatherapy protocol that all system hospitals employed, the
community hospital’s implementation was fortified by this EBP project that included: (a)
engaging the hospital’s newly appointed nurse PCs through DNP student-facilitated meeting
discussions regarding how to promote aromatherapy use and (b) providing DNP Student-led
Lunch & Learn presentations and Rounding for Results sessions on the surgical-orthopedic unit
to promote aromatherapy use.
Goals of this intervention were: (a) for the community hospital’s surgical-orthopedic unit
to meet or exceed the Hospital Consumer Assessment of Healthcare Providers and Systems
(HCAHPS) average score for Magnet hospitals based on raw, unadjusted scores in the NRC
Picker database target for pain management patient experience at all hospitals and (b) for all
appropriate surgical-orthopedic unit patients to receive an offer of lavender aromatherapy as an
option to help manage pain.
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The surgical-orthopedic unit was selected for the Lunch & Learn presentations and
Rounding for Results sessions because its patients were more likely to have acute pain, with or
without chronic pain, than patients in non-surgical units, who were more likely to have only
chronic pain. Surgical-orthopedic patients commonly experienced both acute pain from
operative procedures and chronic pain from osteoarthritis in non-operative joints (Doi, Shimoda,
& Gibbons, 2014). Aromatherapy has been associated with positive effect for both acute and
chronic pain, but the magnitude of effect is greater with acute pain (Lakhan, Sheafer, & Tepper,
2016). Therefore, aromatherapy was likely to benefit the pain experience of patients on this unit
to a greater magnitude than those on non-surgical units.
Problem Statement
Most post-operative patients report unsatisfactory pain management that can limit
surgical recovery and result in deconditioning, hypercoagulability, respiratory compromise,
decreased bowel motility, and chronic pain (Chou et al., 2016). NPPMIs are recommended in
addition to multimodal analgesic medications in consensus guidelines to improve pain
management and decrease reliance on opioids (Chou et al., 2016; Kim et al., 2007; Mack et al.,
2014; RNAO, 2013). Opioid medication risks include constipation, opioid-induced sedation,
respiratory depression, and even death (Czarnecki & Turner, 2018).
Use of aromatherapy with lavender essential oil is a NPPMI (Buckle, 2015). Clinical
research studies of lavender aromatherapy have demonstrated improvement in pain intensity,
patient satisfaction with pain management, and decreased utilization of opioid medication
(Bagheri-Nesami, Espahbodi, Nikkhah, Shorofi, & Charati, 2014; Heidari Gorji et al., 2015;
Irmak Sapmaz et al., 2015; Johnson et al., 2016; Karaman et al., 2016; Kim et al., 2007; Kim et
al., 2006; Lakhan et al., 2016).
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Clinical observations and documentation audits of patient pain management at the health
system, including the study community hospital, demonstrated that NPPMIs were not routinely
provided to patients with pain (Appendix A). In those patients who received NPPMIs, body
positioning to decrease pain was the most frequently documented and observed intervention.
This prompted a dialogue with clinical experts and subsequent literature review of lavender
aromatherapy that resulted in the selection of lavender aromatherapy as a new NPPMI for all
health system hospitals.
This practice change, the initiation of nurse-directed aromatherapy, required the
implementation science approach of the Iowa model of EBP to optimize adoption and
sustainment (Cullen & Adams, 2012; Cullen et al., 2018). The focus of this EBP project was to
improve pain management at the community hospital through fortifying the practice change of
aromatherapy by engaging change agents, an Iowa model implementation strategy, including: a
DNP student who provided Lunch & Learn presentations and Rounding for Results sessions on
the surgical-orthopedic unit and four nurse PCs who promoted use of lavender aromatherapy on
their units.
Use of the Iowa model strategy of change agents to guide lavender aromatherapy
implementation for post-operative patients resulted in improved HCAHPS pain management
scores. DNP student-led unit-based Lunch & Learn presentations (Appendix I), DNP studentfacilitated nurse PC meeting discussions regarding how to promote aromatherapy use (Appendix
J), and computer-based module completion (Appendix E) promoted the practice change of nursedirected lavender aromatherapy for pain management by creating interest and awareness and
building knowledge and commitment. DNP student-led Rounding for Results sessions promoted
action and adoption of the lavender aromatherapy (Appendix K). Ongoing nurse PC meetings
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and activities were identified as a method to pursue integration and sustainment through peer
coaching and sharing of implementation outcome data with peers. Lavender aromatherapy EMR
reports and monthly reports of inhaler usage provided by the hospital supply chain team were
utilized to measure adoption of the practice change of nurse-directed lavender aromatherapy.
The project implemented and evaluated an Iowa model-guided initiative to fortify the
community hospital’s implementation of nurse-directed lavender aromatherapy for pain
management, through DNP student and nurse PC change agents.
Purpose Statement
The purpose of this EBP project was to employ change agents (an Iowa model EBP
dissemination strategy) to fortify implementation of nurse-directed lavender aromatherapy for
patient pain management in a community hospital.
Practice Question
The primary clinical question for this project was:
Was the strategy of change agents effective in achieving implementation of nursedirected lavender aromatherapy to improve pain management experience in adult patients
on a surgical-orthopedic unit of a community hospital?
Aims and Objectives
Aim
To increase the surgical-orthopedic unit patient HCAHPS pain management experience
score to equal or above the Magnet average of hospitals in the NRC Picker database and to
achieve a consistent practice of 100 % of appropriate patients being offered lavender
aromatherapy by the end of the third quarter of FY 2019.

CHANGE AGENT IMPACT ON PAIN THROUGH AROMATHERAPY

17

Objectives
•

To build knowledge and commitment of clinical nurses regarding implementation of
NPPMIs, particularly lavender aromatherapy.

•

To engage nurse PCs to promote action and adoption of lavender aromatherapy for pain
management.

•

To promote integration and sustained use of lavender aromatherapy, through evaluation
of HCAHPS pain experiences scores, lavender inhaler consumption reports, and EMR
aromatherapy documentation reports.
Review of the Literature

Aromatherapy for Pain Management
A database search including PubMed and CINAHL using search terms of aromatherapy
and pain and pain management was conducted with the help of a research librarian. The search
inclusion criteria were: the population must include adults cared for in a medical-surgical unit or
procedural/surgical area, the intervention must include aromatherapy with lavender, the outcome
of self-reported pain must be reported, the study must have an experimental design and control,
peer-reviewed journal publication, English language, and publication years of 2006 through
2016.
Six randomized controlled trials of lavender essential oil inhalation for acute pain were
identified. All were conducted in an academic university or medical centers in three locations:
two studies conducted in Iran, two in Turkey, and two in New York city (Bagheri-Nesami et al.,
2014; Heidari Gorji et al., 2015; Irmak Sapmaz et al., 2015; Karaman et al., 2016; Kim et al.,
2007; Kim et al., 2006) (Appendix L). Patient populations in five of these studies were selected
because they were undergoing procedures that are typical of the hospital setting and produce
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acute pain including: hemodialysis access cannulation, peripheral venous cannulation, cardiac
surgery with sternotomy, gastric banding, and breast biopsy. The remaining study focused on
the diagnosis of renal colic that is a medical diagnosis associated with acute pain. Aromatherapy
with lavender inhalation was noted to have a significant effect on the outcome of self-reported
acute pain as compared to placebo in five of the six studies with reported p values ranging from
< .001 to < .05 (Bagheri-Nesami et al., 2014; Heidari Gorji et al., 2015; Irmak Sapmaz et al.,
2015; Karaman et al., 2016; Kim et al., 2007). Kim and colleagues’ (2006) initial study of
patients undergoing breast biopsy did not note a significant difference in pain intensity between
those who received placebo and those who received lavender aromatherapy, but both groups
reported low levels of pain intensity. Reduction in opioid use was observed in one study (Kim et
al., 2007).
In addition, a meta-analysis and a large observational study fortified the evidence for
aromatherapy for pain (Johnson et al., 2016; Lakhan, Sheafer, & Tepper, 2016). A systematic
review and meta-analysis of pooled data from twelve randomized controlled trials in which
aromatherapy was an intervention for acute or chronic pain concluded that there was a
statistically significant reduction in pain intensity and a large effect size (Lakhan, Sheafer, &
Tepper, 2016). The meta-analysis demonstrated a larger magnitude of effect for acute pain than
chronic pain. A large observational trial of over 5,000 administrations of lavender essential oil
in a hospital system in the mid-western United States noted a mean reduction in pain intensity of
three points on an 11-point scale and no associated serious safety events (Johnson et al., 2016).
The National Institutes of Health National Center for Complementary and Integrative
Health (2016) provided the opinion that current aromatherapy research includes only studies of
insufficient size and quality to warrant a recommendation of effectiveness of its use for symptom
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relief, including pain management. This contrasts with the findings of the meta-analysis,
randomized controlled trials, and observational study (Bagheri-Nesami et al., 2014; Heidari Gorji
et al., 2015; Irmak Sapmaz et al., 2015; Johnson et al., 2016; Karaman et al., 2016; Kim et al.,
2007; Lakhan et al., 2016).
Change Agents
Database queries including OVID® Medline, CINAHL, SCOPUS, and Clinical Key for
Nursing using search terms of “Pain Champion” and “Pain Resource Nurse” were conducted.
These terms are used interchangeably in the literature. The search inclusion criteria were: peerreviewed journal publications, English language, and no limit on publication years. A search of
Pain Management Nursing journal from 2007 to present using the search term “Pain Resource
Nurse” was also conducted. Hand searches of articles and the references in the chapter on
implementation by Cullen and colleagues (2018) were performed. Articles were organized by
hierarchy of evidence and scanned content that included nurse PC program evaluations or the
role of APRN pain champions, since the DNP student in this project was an APRN.
The only randomized controlled trial of the effectiveness implementation of a nurse PC
program, took place in a 650-bed university-affiliated hospital in Iceland (Gunnarsdottir et al.,
2017). Twelve adult medical-surgical units were randomized to initial program implementation
and eleven units served as the control, with a plan to implement the program on those units in the
future. A three-day training nurse PC course was provided to 24 nurses. The course was
followed by a six-month process in which each nurse PC was mentored by a clinical nurse
specialist (CNS). Clinical outcomes were measured before and after implementation with: (a)
pain management index that evaluated pain with both pain intensity and the strength of
analgesics a patient received and (b) a standardized pain questionnaire (Cleeland et al., 1994;
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Gordon et al., 2010). Two nursing outcomes were measured pre and post implementation: (a)
nurses’ selection of an appropriate pain assessment tool, based on medical records
documentation review and (b) a standardized knowledge and attitudes survey provided to all
nurses in the hospital (Ferrell & McCaffery, 2014). No significant differences were found in
patient pain intensity, patient pain experience, or nursing knowledge and attitudes regarding pain
management. Significant improvement in nurses’ selection of appropriate pain assessment tools
was noted. The study was well designed because: (a) control nursing units were measured in
comparison with units with nurse PCs, (b) the number of nursing units included was adequate for
statistical power, and (c) both patient and nursing outcomes were measured. There were a
number of limitations including: (a) the intervention focused on improving nursing knowledge,
but there was no assessment of the quality of the multidisciplinary practice environment that is
essential for pain management; (b) the pre and post assessment interval was six-months, despite
the authors’ acknowledgement that transition to the nurse PC role often requires a year or more;
(c) the authors asserted that informing the leadership of the program ensured support, but did not
measure the degree of leadership support nurses experienced; and (d) a lack of process or
effectiveness measures for the mentorship phase.
Thirteen descriptive, qualitative and mixed methods pain champion program evaluations
identified challenges, facilitators, and benefits. Challenges included: (a) sustaining leadership
support, (b) time for nurse PCs to attend meetings, (c) incorporating the role during the workday,
(d) visibility to peers, (e) receptiveness of nurse colleagues, (f) the slow pace of practice change,
and (g) a focus on regulatory outcomes over patient outcomes (Allen et al., 2018; Ferrell, Grant,
Ritchie, Ropchan, & Rivera, 1993; Ladak et al., 2013; McCleary, Ellis, & Rowley, 2004; Tong et
al., 2019). Facilitators included: (a) initial didactic education on pain management and the pain
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champion role, (b) nursing unit leadership support, (c) dedicated time for meetings and activities,
(d) clear role expectations, (e) clinical mentors, and (f) dedicated acute pain provider teams
(Ladak et al., 2013; McCleary, Ellis, & Rowley, 2004; Overstreet, 2012; Tong et al., 2019).
Benefits included: (a) improved and sustained nursing knowledge, (b) sustained confidence in
pain management, (c) improved documentation of pain assessment, (d) adoption of pain
management practice changes, (e) improved patient pain experience, (f) decreased pain
prevalence, and (g) improved patient and clinician communication about pain management
(Allen et al., 2018; Eaton, Gordon, & Doorenbos, 2013; Ferrell et al., 1993; Grant, Ferrell,
Hanson, Sun, & Uman, 2011; Greenway & Corston, 2016; Holley, McMillan, Hagan, Palacios,
& Rosenberg, 2005; Ladak et al., 2013; McCleary, Ellis, & Rowley, 2004; McMillan, Tittle,
Hagan, & Small, 2005; Overstreet, 2012; Paice, Barnard, Creamer, & Omerod, 2006; Telford,
Nichols, & Watson, 2019; Tong et al., 2019).
The role of the APRN as a pain champion included: (a) patient assessment and care
planning; (b) education of nurses and other clinicians; (c) developing a culture of trust with and
among clinical nurses and other disciplines; and (d) protocol implementation including
assessment of barriers, practice reminders, medical record audits (Kaasalainen et al., 2015;
McCleary et al., 2004). Barriers in APRN implementation of protocols included: less APRN
time at the bedside than clinical nurses, competition of EBP protocols with other change
initiatives, clinical nurse resistance to change, and turnover in clinical nurses (Kaasalainen et al.,
2015; McCleary et al., 2004). Facilitators in APRN implementation of protocols included: (a) a
dedicated APRN pain champion was responsible for protocol oversight, (b) senior leadership
supported the APRN role in protocol implementation, (c) an APRN provided education and
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mentoring of clinical nurses regarding the protocol, and (d) an APRN applied advanced
knowledge of pain medications to care planning (Kaasalainen et al., 2015).
Theoretical Framework
The Iowa Model of EBP Implementation
Implementation of evidence to practice at the health system was informed by the Iowa
model of EBP for: (a) identification of the practice improvement opportunity, (b) evaluation and
synthesis of evidence, and (c) evidence-based dissemination strategies (Cullen & Adams, 2012;
Cullen et al., 2018). The Iowa model process for identification of the practice improvement
opportunity, review of the literature, and synthesis of evidence was completed prior to the health
system lavender aromatherapy pilot. Evidence for the use of NPPMIs was based on CPG
evidence-based recommendations (Chou et al., 2016; Mack et al., 2014). A literature review of
aromatherapy, a NPPMI that is feasible nurse-directed implementation, provided additional
evidence (Bagheri-Nesami et al., 2014; Heidari Gorji et al., 2015; Irmak Sapmaz et al., 2015;
Johnson et al., 2016; Karaman et al., 2016; Kim et al., 2007; Lakhan et al., 2016).
The Iowa model provided a table of evidence-based implementation strategies across four
phases and two areas of focus for this EBP project, which is shown in Appendix M. The phases
were: (a) create interest and awareness, (b) build knowledge and commitment, (c) promote action
and adoption, and (d) purse integration and sustained use. The areas of focus were: (a)
connecting with clinicians, organizational leaders, and key stakeholders; and (b) building
organizational support.
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Methodology
Logic Model
In addition to appraisal and synthesis of evidence, this EBP implementation required an
assessment of the context of practice and the necessary resources, stakeholders, and processes to
achieve the desired patient outcomes (Melnyk & Fineout-Overholt, 2011; Millar, Simeone, &
Carnevale, 2001). A logic model was selected as the program planning tool (McCawley, 2001).
The logic model was used to: (a) identify the priorities to be addressed in the project; (b)
compare the state of clinical care prior to the project to the desired outcomes; (c) identify inputs
and outputs needed to achieve these outcomes; and (d) identify assumptions and external factors
that may impact the success of the project (McCawley, 2001; Millar et al., 2001). Project
outcomes were segmented into three temporal types: short-term, medium-term, and long-term
(McCawley, 2001; Millar et al., 2001; Taylor-Powell, Jones, & Henert, 2003).
The logic model outcomes aligned with the four dissemination phases of the Iowa model:
(a) short-term outcomes included creation of interest and awareness of the need for the desired
practice and knowledge and commitment required for the practice change, (b) medium-term
outcomes included the action and adoption of the practice change, and (c) long-term outcomes
included the integration and sustainment of the practice change and its impact on the identified
need (Cullen et al., 2018; McCawley, 2001; Taylor-Powell et al., 2003) (Appendix N).
Situation.
Adult patients, ages 18 and older, in the community hospital rated their pain management
experience during hospitalization with the Hospital Consumer Assessment of Healthcare
Providers and Systems (HCAHPS) survey. The health system HCAHPS pain experience score
target for all hospitals, including the community hospital, was to meet or exceed the average
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score for Magnet hospitals based on raw, unadjusted scores in the NRC Picker database. The
hospital had not met this target score in over 12 months, scoring at the 33rd percentile. As of
January 12, 2019, the community hospital FY 2019 performance to date improved to just below
the 50th percentile as compared to all NRC database hospitals but remained at the 43rd percentile
as compared to NRC database Magnet hospitals. According to the NRC database analysis report,
the community hospital’s pain management experience score was one of key drivers of patients’
overall rating of the community hospital, on a zero to 10 scale. The surgical-orthopedic unit
ranked third among its six community hospital units for pain management experience, scoring at
the 30th percentile over the past 12 months.
Since 2014, the community hospital had worked to implement the Assessment and
Management of Acute Pain in the Hospitalized Adult CPG that recommended cognitive NPPMI.
However, during annual surveys by the health system’s pain management APRN in 2016, 2017,
and 2018, patients did not receive cognitive NPPMIs in the surgical-orthopedic unit or the other
five inpatient units. Similarly, other hospitals in the health system had low utilization of
NPPMIs.
Due to the lack of cognitive NPPMIs, lavender aromatherapy was recommended by the
health system for nurses at each hospital to offer to patients. This was particularly important for
the community hospital and its surgical-orthopedic unit due to below-target patient pain
management experience scores. The selection of lavender aromatherapy was based on the
literature review findings of the effectiveness of lavender aromatherapy for improved pain
management in both acute and chronic pain, with a greater magnitude of benefit in acute pain
(Lakhan, Sheafer, & Tepper, 2016). In the placebo-control studies of lavender essential oil
aromatherapy for acute pain, patients who received lavender aromatherapy demonstrated less
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pain intensity than those who received placebo (Bagheri-Nesami, Espahbodi, Nikkhah, Shorofi,
& Charati, 2014; Heidari Gorji et al., 2015; Irmak Sapmaz et al., 2015; Karaman et al., 2016;
Kim et al., 2007). The magnitude of effect of lavender aromatherapy, observed in a large
observational trial in hospitalized patients, was a mean improvement in pain intensity score of
three points on a 10-point scale (Johnson et al., 2016).
Priorities.
Since the community hospital resided in the state of Maryland, its patient experience
scores determined 50% of the revenue from quality-based reimbursement (QBR) program
(Health Services Cost Review Commission [HSCRC], 2017). In other states, patient experience
scores comprised only 25% of the value-based reimbursement program (HSCRC, 2017).
Although the pain experience scores were removed from the FY 2019 QBR program, the overall
rating of the hospital continued to be included and pain management experience was a key driver
of the community’s hospitals overall rating. Over a million dollars of the community hospital’s
annual reimbursement was at risk under the QBR program (HSCRC, 2017).
At the start of the project, the health system’s annual nursing goals included
implementation of aromatherapy in all hospitals. This logic model was developed to plan for the
community hospital’s implementation of aromatherapy, fortify implementation with change
agents, and focus on the surgical-orthopedic unit.
Inputs.
Lavender aromatherapy inhalers were placed in a dedicated bin in each nursing unit’s
supply rooms by the supply chain team at the nurse managers’ direction. The inhalers were
financed through the unit nursing budget. The inhalers used in the project had a three-month
potency when opened, so only one inhaler was typically needed for each patient encounter.
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Time and resources for training clinical staff on lavender aromatherapy inhalers included:
•

A 15-minute aromatherapy computer-based module for 25 clinical nurses on the
surgical-orthopedic unit and four of the hospital’s nurse PCs.

•

Three 15-minute Lunch & Learn presentations with surgical-orthopedic unit
nurses that occurred during a week-day day-shift, a week-day night-shift, and a
week-end day shift.

•

Refreshments for the three surgical-orthopedic unit-based Lunch & Learn
presentations and two nurse champion meetings, supplied by the DNP student.

•

Forty lavender aromatherapy inhalers were provided free of charge by the vendor
through the hospital’s supply chain team and distributed to nurse PCs and clinical
nurses on the surgical-orthopedic unit and other clinical staff during nurse PC
meetings, Lunch & Learn presentations, and Rounding for Results sessions.

Outcomes.
Short-term outcomes.
Surgical-orthopedic unit clinical nurses, nurse PCs, and other clinicians articulated:
•

Lavender aromatherapy benefits, patient assessment protocol and patient
education key points.
o The target for this outcome was all surgical-orthopedic unit clinical nurses
and nurse PCs completed the computer module successfully with a score
of 80% on the module evaluation.
o The hospital nurse educator provided a de-identified health system
learning management system report of lavender aromatherapy module
completion.
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Intent to offer lavender inhalers to patients.
o The target for this outcome was 100% of surgical-orthopedic unit nurses
verbalize intent to offer lavender during DNP student weekly Rounding
for Results sessions.
o Evaluation was recorded on the DNP student surgical-orthopedic unit
Rounding for Results form (Appendix K).

•

Skill to appropriately use and teach patients to use lavender inhalers.
o The target for this outcome was 100% of surgical-orthopedic unit patients
are observed to appropriately use lavender inhalers by the end of the
fourth week of the DNP Rounding for Results sessions.
o Evaluation was recorded on the DNP student surgical-orthopedic unit
Rounding for Results form (Appendix K).

•

Nurse leaders established recommended par levels of lavender inhalers.
o The target for this outcome was each week during DNP Rounding for
Results sessions, the number of lavender inhalers was observed to be at
par level for the day.
o Evaluation was recorded on the DNP student surgical-orthopedic unit
Rounding for Results form (Appendix K).

•

Nurse leaders mentioned lavender inhalers during nurse leader patient rounds.
o The target for this outcome was each week during DNP student Rounding
for Results sessions, a verbal check-in with the nurse manager or charge
nurse validated that lavender aromatherapy was mentioned during their
nurse leader rounds with patients.
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o Evaluation was recorded on the DNP student surgical-orthopedic unit
Rounding for Results form (Appendix K).
Medium-term outcomes.
•

Patients were screened for aromatherapy during the first four weeks of the project,
during which the Rounding for Results sessions occurred.
o The target for this outcome was 20% of adult surgical-orthopedic unit
patients during week one of the project and increasing by 20% increments
each week of the Rounding for Results sessions, to 80% on week four,
measured by observations of documentation and electronic medical record
reports.
o Observations of documentation of screening of patients for lavender
intolerance was recorded on the DNP student surgical-orthopedic unit
Rounding for Results form (Appendix K).
o Weekly EMR aromatherapy documentation reports were generated to
provide percentage of patients with documentation of screening for
contraindication or reaction to lavender essential oil (Appendix O). These
reports were run in one-week time-periods with only aggregate data
reported.

•

Lavender inhalers were offered to appropriate patients in the surgical-orthopedic
unit during the Rounding for Results sessions.
o

The target for aromatherapy offer was measured by documentation of
patients’ verbal agreement decision in both the Rounding for Results
observations and the weekly EMR aromatherapy documentation reports.
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The target for aromatherapy offer to patients who did not have
contraindication to lavender was 20% of adult surgical-orthopedic unit
patients during week one of the project, increasing by 20% increments
each week of the Rounding for Results sessions, to 80% of patients in
week four. To avoid placing undue pressure on nurses or patients no
target was set for percent of patients without a contraindication who
agreed to use the lavender inhaler.
o Observations of documentation of patients’ verbal agreement decision to
the offer of lavender inhaler were recorded on the DNP student surgicalorthopedic unit Rounding for Results form (Appendix K).
o Weekly EMR aromatherapy documentation reports provided percentage of
patients without a contraindication to lavender aromatherapy who had
documentation of the patient’s decision to the offer of lavender inhaler,
including the percent of patients who verbally agreed to use it (Appendix
O).
•

Patients self-administered the lavender inhalers as intended as measured by
observations of patient use on weekly Rounding for Results sessions.
o The target for this outcome was 100% of surgical-orthopedic unit patients
were observed to self-administer lavender inhalers by the end of the fourth
week of the DNP student Rounding for Results sessions.
o Observations were recorded on the DNP student surgical-orthopedic unit
Rounding for Results form (Appendix K).
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Long-term outcomes.
•

Surgical-orthopedic unit patients’ pain was well managed as evidenced by pain
experience scores.
o The target for this outcome was surgical-orthopedic unit pain management
experience scores at or above the NRC Picker database average score for
Magnet hospitals by the end of the third quarter of FY 2019.
o This outcome was measured by NRC Picker database reports that finalized
eight weeks after the end of the project.

•

All appropriate patients were offered lavender inhalers to help manage pain in the
two-week period after the Rounding for Results sessions ended.
o The target for documentation of patients’ verbal agreement decision in
period EMR report outcomes was 100% of adult surgical-orthopedic unit
patients without a contraindication to lavender. To avoid placing undue
pressure on nurses or patients no target was set for percent of patients
without a contraindication who agreed to use the lavender inhaler.
o Weekly EMR aromatherapy documentation reports provided percentage of
patients without a contraindication to lavender aromatherapy who had
documentation of the patient’s decision to the offer of lavender inhaler,
including the percent of patients who verbally agreed to use it (Appendix
O).
o Monthly supply chain reports evaluated if consumption matched the
number of patients with documentation of agreement to use lavender
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aromatherapy noted in the EMR report for all three months of the project.
There was no target for consumption as this was a validation measure.
Assumptions.
The following logic model pre-project assumptions were met and facilitated
implementation success:
•

Lavender aromatherapy in the surgical-orthopedic unit was embraced by surgicalorthopedic unit clinicians and patients as a valuable pain management
intervention as assumed, but at a slower than anticipated rate.

•

Surgical-orthopedic unit patients agreed to use lavender aromatherapy.

•

Surgical-orthopedic unit clinical nurses implemented and completed the protocol
but there were challenges such as uncertainty of inhaler location,
misunderstanding of the eligible patient population, failure to screen all patients,
nurse bias that patients receiving opioids would decline, and missing
documentation of aromatherapy screening and offer.

•

The Iowa Model strategy of DNP student and nurse PC change agents was a valid
approach for lavender aromatherapy implementation in the surgical-orthopedic
unit population.

•

The community hospital CNO and the hospital Vice President for Medical Affairs
supported nurse-directed lavender aromatherapy.
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External Factors.
The following external factors were evaluated to determine influence on the success of
this logic model:
•

Lavender inhaler supply.
o Supply remained available and there were no recalls or manufacturer
interruptions. The supply of lavender inhalers was sourced from one
vendor in the Midwestern United States that supplied at least one other
large health system.

•

Regulatory reviewers were an external factor that may have altered project
implementation.
o A Joint Commission presentation at the 2019 American Society of Pain
Management Nursing conference noted that regulatory reviewers may
have concerns because aromatherapy is not approved by the Food and
Drug Administration (FDA) for the treatment of pain (Campbell, 2018).
o The health system patient and family education material informed patients
that aromatherapy could help patients manage pain, was not intended for
treatment of disease, and was not regulated by the FDA.
o The Joint Commission did not mention aromatherapy in its August 2018
brief about NPPMIs (Joint Commission, 2018).
o No regulatory reviews occurred at the community hospital during project
implementation.

•

The Maryland hospital QBR program continued to include patient experience
scores as 50% of the basis for QBR reimbursement (HSCRC, 2017).
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Setting
The setting was an adult inpatient surgical-orthopedic unit at a community hospital in a
10-hospital system.
Study Population
Inclusion criteria.
•

Community hospital clinical nurses and the nurse manager practicing on the adult
inpatient surgical-orthopedic unit and nurse PCs were included in the project.

•

Adult inpatients or observation patients, ages 18 and older, experiencing acute or
chronic pain or who have anticipated procedural pain, and who were cared for by
clinical nurses and the nurse manager on the adult inpatient surgical-orthopedic
unit were included in the project.

•

The community hospital’s lavender aromatherapy policy had the following
exclusion criteria that aligned with those in the health system’s protocol: Adult
inpatients or observation patients, ages 18 and older, experiencing acute or
chronic pain or who were anticipated to have procedural pain.

Exclusion criteria.
•

Nurses in the community hospital practicing in units other than the surgicalorthopedic unit nurses or were not nurse PCs were excluded.

•

Pregnant women, prisoners, or non-English language speakers being cared for on
the adult inpatient surgical-orthopedic unit were excluded. Adults unable to
verbally agree to receive lavender aromatherapy were excluded.

•

The community hospital’s lavender aromatherapy policy had the following
exclusion criteria that aligned with those in the health system’s protocol:
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o Any patient-reported intolerance or allergy to the lavender plant or
essential oil including true allergy with anaphylaxis, rash, and/or
intolerance such as headache, nausea, or dizziness induced by the odor.
o Any cognitive or physical condition that rendered the patient unable to: (a)
answer the aromatherapy assessment question regarding intolerance and
allergy, (b) indicate verbal agreement to use the lavender inhaler, or (c)
participate in education about lavender aromatherapy.
Subject Recruitment
This was an EBP project focused on the intervention of the Iowa model strategy of
change agents in the practice environment to fortify the hospital’s lavender aromatherapy
implementation, a hospital-approved NPPMI.
Nurses from the community hospital’s surgical-orthopedic unit and the nurse PC program
were recruited to participate in this project. During the third quarter of FY 2019, the DNP
student interacted with surgical-orthopedic unit clinical nurses, the surgical-orthopedic unit nurse
manager, and community hospital nurse PCs. The DNP student: (a) provided Lunch & Learn
sessions; (b) encouraged clinical nurses and nurse PCs to complete the computer-based module
training on aromatherapy; (c) conducted Rounding for Results sessions that included observation
of nursing documentation of aromatherapy in medical records, queries of nurses regarding their
intent to offer aromatherapy, and observations of patients use of lavender aromatherapy inhalers;
and (d) led discussions with nurse PCs about how to promote aromatherapy in the practice
setting. The intent of the observations during the Rounding for Results sessions was to determine
if the hospital’s policy and procedure for nurse-directed lavender aromatherapy was followed, to
validate correct patient use of lavender aromatherapy inhalers, and provide re-education if
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correct use was not observed. No patient intervention other than nurse-directed lavender
aromatherapy, a hospital-approved NPPMI, was provided. No identifiable patient information
was recorded. The orthopedic-surgical unit Rounding for Results form did not include patient
identifiers (Appendix K).
Consent Procedure
No consent process was performed because this was an EBP project to foster
implementation of a hospital-approved nurse-directed NPPMI. As per the community hospital’s
aromatherapy policy, clinical nurses queried patients for self-reported contraindication or
reaction to lavender essential oil, provided patient education regarding aromatherapy, and asked
patients for verbal agreement to use aromatherapy before they provided lavender inhalers to
patients. The verbal agreement process was included in the health system protocol for lavender
aromatherapy for pain management and community hospital’s nurse-directed aromatherapy
policy and procedure based on the advice of the health system’s legal counsel, who also advised
that written consent was not required. Any patients who self-reported a contraindication or
reaction to lavender essential oil were not offered the lavender inhaler. No additional process to
obtain consent occurred in this EBP project.
Risks/Harms
The potential risk to patients included harm due to allergic reaction or intolerance to
lavender essential oil. Patients who reported a history of allergy or sensitivity to lavender
essential oil were not offered an inhaler. A pulmonologist specializing in asthma management
was consulted and after review of the evidence, recommended against including asthma on the
list of contraindications (A. Shorr, personal communication, May 11, 2018). Essential oils used
in this project did not contain proteins and were highly unlikely to cause a Type I allergic
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reaction (Buckle, 2015). Allergy with IgG antibodies was a risk with exposure to essential oils,
the same risk as any compound (J. Baraniuk, personal communication, May 23, 2018).
However, this type of allergic reaction to essential oils has not been commonly reported (Buckle,
2015). Use of lavender essential oil has not been associated with clinical worsening of asthma
(Buckle, 2015). Seven clinical trials reported no serious patient events (Bagheri-Nesami,
Espahbodi, Nikkhah, Shorofi, & Charati, 2014; Heidari Gorji et al., 2015; Irmak Sapmaz et al.,
2015; Johnson et al., 2016; Karaman et al., 2016; Kim et al., 2006; Kim et al., 2007). Two health
systems, Allina Health and New York Presbyterian, reported no serious patient or associate
safety events with use in multiple hospitals over multiple years (Joswiak et al., 2016; J. Seley,
personal communication, May 30, 2018). No patient, visitor, nurse, physician, or other associate
safety events were reported in the product trial at two of the community hospitals’ sister health
system hospitals in August 2018. No patient, visitor, nurse, physician, or other associate safety
events were reported during this project.
No demographic or other identifying data was captured for this project and only
aggregate data were reported. There was no risk of patient identification in the collected or
reported data.
Potential benefits included:
•

Nurses may have experienced increased role satisfaction through the opportunity
to impact patients’ pain experience and personal wellness using the lavender
inhalers for personal use.

•

Patients may have experienced improved pain management through use of
lavender aromatherapy including decreased need for analgesic medications,
including opioids. Patients who were observed to be using the inhaler incorrectly
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experienced enhanced safety and effectiveness of aromatherapy through reeducation that was provided by the DNP student.
Subject Costs and Compensation
There were no costs to subjects for the aromatherapy inhalers. The aromatherapy
inhalers were non-chargeable items provided through the unit cost centers. Clinical nurses were
provided lavender inhalers for personal use as part of the educational sessions and these were
supplied free of charge from the lavender inhaler vendor. Clinical nurses on the surgicalorthopedic unit and nurse PCs participated in training and meetings during worked hours.
Refreshments for the PC meetings and Lunch & Learn sessions were provided by the DNP
student.
Study Interventions
The study interventions employed the strategy of a DNP student and nurse PC change
agents through the following activities:
•

Encouragement of nurses to complete an aromatherapy computer-based training module
during the following interactions: nurse PC meetings, Lunch & Learn presentations, and
Rounding for Results sessions.

•

Two DNP student-facilitated nurse PC meeting discussions regarding how to promote
aromatherapy use (Appendix J).

•

Three Lunch & Learn aromatherapy presentations for surgical-orthopedic unit clinical
nurses (Appendix H).

•

Four DNP student-led Rounding for Results sessions with clinical nurses on the surgicalorthopedic unit (Appendix K).
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Development of reports including supply chain monthly lavender inhaler usage and EMR
aromatherapy documentation reports that nurse PCs reviewed at their meetings and
planned to review on an ongoing basis.

Outcomes Measured
Short-term, medium-term, and long-term outcomes were measured as noted in the Logic
Model (Appendix N).
Project Timeline
Congruent with the community hospital aromatherapy implementation action plan in
Appendix P, the project began on February 14, 2019 and was completed on March 30, 2019.
Lunch & Learn presentations occurred on February 14, 2019 and February 16, 2019. Rounding
for Results sessions occurred on February 19, 2019; February 26, 2019; March 5, 2019; and
March 12, 2019. Nurse PC discussions occurred on February 28, 2019 and March 27, 2019.
Weekly aromatherapy reports contained data from February 17, 2019 through March 30, 2019.
The action plan incorporated the Iowa model recommendation to include strategies for all four
phases of practice change (Cullen et al., 2018).
Resources Utilized
Lavender aromatherapy inhalers for patients were financed by the budgets of all inpatient
nursing units, including the surgical-orthopedic unit, and located in a dedicated space on the
units’ supply rooms.
Forty lavender aromatherapy inhalers were provided to clinical staff, including four nurse
PCs, to try personally and were secured free of charge by the vendor through the hospital’s
supply chain team.
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Time and resources for training clinical staff on lavender aromatherapy inhalers was
provided. This included:
•

A 15-minute aromatherapy computer-based module for 24 clinical nurses on the
surgical-orthopedic unit and four hospital nurse PCs.

•

Three 15-minute Lunch & Learn sessions for nurses at three sessions.

•

Two aromatherapy discussions at the regular monthly nurse PC meetings that
were approximately 30 minutes in length.

•

Refreshments for three nurse PC meetings and three surgical-orthopedic unitbased Lunch & Learn sessions for clinical nurses on the surgical-orthopedic unit
were supplied by the DNP student.
Evaluation Plan

Observational data was captured on the DNP student Rounding for Results form with no
patient identifiable data (Appendix K). EMR reports of aggregate data derived from
aromatherapy documentation fields on the surgical-orthopedic unit were generated weekly by the
health system informatics team and supplied to the DNP student as de-identified cases
(Appendix O). Inhaler consumption reports were supplied by the hospital supply chain team via
email to the DNP student. A password-protected Excel workbook was used for data capture and
analysis (Appendix Q).
Data Analysis, Maintenance & Security
The data analysis plan was comprised by three appendices: (a) plan for project primary
clinical question data analysis (Appendix R), (b) plan for project aims data analysis (Appendix
S), and (c) plan for project logic model outcomes data analysis (Appendix T). No tests of
statistical significance were performed. Descriptive statistics are provided for categorical and
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numerical data compiled from the DNP student Rounding for Results form, the weekly deidentified EMR aromatherapy documentation reports, and the hospital supply chain team inhaler
consumption reports. Qualitative data including barriers, facilitators and comments compiled on
the DNP student Rounding for Results form were categorized and summarized in the Excel
workbook and noted in the reporting of results. Weekly EMR aromatherapy documentation
report data were transcribed into the same Excel workbook as the Rounding for Results forms.
The Excel worksheets were queried for empty cells. No identified data were stored. The Excel
workbook was a password-protected file stored on a password-protected health system-owned
laptop with the organizational antivirus and threat protection software. Backup files were
password protected and stored on a password-protected and encrypted USB drive compliant with
the health system standards. No paper copies of Rounding for Results forms were stored. No
paper copies or electronic files of the EMR aromatherapy documentation reports were stored.
Anticipated Findings
Rates of clinical nurse and patient participation were anticipated to be low initially and to
increase over the course of the project. This pattern was anecdotally observed in the pilot at
another hospital in the health system where it was noted that nurse interest increased when
patients described the effectiveness to their nurses and when nurses observed a lessening of pain
because of the use of the lavender inhaler.
Anticipated barriers were: (a) nurses’ hesitancy to add another task to their already busy
clinical day and (b) patient disinterest in aromatherapy, although this was not observed in the
pilot.
It was anticipated that the addition of nurse PC support and DNP student Rounding for
Results sessions would promote lavender aromatherapy utilization. Sustainment and integration
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of aromatherapy use through the nurse PC program’s ongoing aromatherapy promotion and data
review was anticipated. Improvement of HCAHPS pain management experience scores was
expected. Decreases in pain intensity and opioid medication use in patients who receive
aromatherapy reported in the literature were possible outcomes.
Results
Primary Clinical Question Results
The results for the primary clinical question “Was the strategy of change agents effective
in achieving implementation of nurse-directed lavender aromatherapy to improve pain
management experience in adult patients on a surgical-orthopedic unit of a community hospital?”
included measures of intervention feasibility and the clinical outcome of improved patient pain
experience (Appendix U).
Interventions Results
The logic model output activities, which engaged change agents, included: three DNP
Student-led Lunch & Learn presentations, four DNP student-led weekly Rounding for Results
sessions and two DNP-facilitated nurse PC discussions. All three interventions were feasible and
the project outcome of implementation of the bundle of all three interventions was met.
Three Lunch & Learn presentations were attended by a total of 21 surgical-orthopedic
unit associates. The range among roles of attendees was: 14 Registered Nurses, six Certified
Nursing Assistants, and one Unit Secretary. The number of attendees per presentations ranged
from five to nine. The mean number of attendees per presentation was seven.
Four DNP student-led weekly Rounding for Results sessions were completed with a total
of 78 patients, a mean of 20 patients evaluated per session, and a range of 18-21 patients per
session.
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Two DNP-facilitated nurse PC discussions were attended by four nurse PCs and three to
four PC program leaders at each session, including the DNP student, with a mean attendance of
7.5 and a range of seven to eight attendees. Although 14 nurse PCs were anticipated to
participate in the program, only four attended either meeting and three attended both meetings.
The nurse PCs represented four of seven inpatient medical-surgical units, including the surgicalorthopedic unit.
Clinical Outcome Results
The intervention of engaging change agents was effective in achieving implementation of
nurse-directed lavender aromatherapy to improve pain management experience in adult patients
on a surgical-orthopedic unit of a community hospital. The surgical-orthopedic unit patient pain
management experience percentile rankings increased during the implementation period. Before
implementation the surgical-orthopedic unit scores were below target. In the first quarter, the
scores were 52.2% positive, ranking in the 12th percentile as compared to Magnet hospitals in the
NRC Picker data base. In the second quarter, the scores were 63.0 % positive, ranking in the 43rd
percentile, but the reliability of the second quarter scores was limited by a small sample size.
After implementation in the third quarter, the surgical-orthopedic unit score increased to 72.2%
positive, ranking at the 78th percentile and exceeding the target. Before implementation the
community hospital score was: (a) below target in the first quarter at 59.3% positive, ranking in
the 31st percentile; and (b) above target in the second quarter at 63.3 % positive, ranking in the
56th percentile. After implementation in the third quarter, the community hospital score
decreased below target at 64.1% positive, ranking at the 46th percentile. Although the surgicalorthopedic unit scores and ranking increased markedly during implementation, the community
hospital ranking decreased slightly, although the score itself increased.
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Project Aims Results
Project aims data are reported in Appendix V.
The first project aim was to increase the surgical-orthopedic unit patient HCAHPS pain
management experience score to equal or above the Magnet average of hospitals in the NRC
Picker database by the end of the third quarter of FY 2019. This aim was met with a score of
72.2% positive that ranked at the 78th percentile.
The second aim was 100% of surgical-orthopedic unit patients who were documented to
have no contraindication to lavender aromatherapy receive an offer of lavender aromatherapy
each of the six weeks of the project. This aim was not met but was nearly achieved.
Based on surgical orthopedic unit EMR data, 33 of 34 eligible patients received the offer,
missing the aim by one patient on week three. The range of weekly percentages was 91.7% on
the third week to 100% on the other five weeks. The mean weekly percentage was 97.1%.
Based on the total of the four weekly Rounding for Results session observations of medical
records, eight of nine patients, 88.89%, who had documentation of no contraindication to
lavender aromatherapy received an offer of lavender aromatherapy. Of the nine patients who
were screened, one declined the offer, so the nurse did not chart the education or response to the
offer. The DNP student re-educated the nurse on the protocol and she verbally indicated she
would correct the documentation when she next charted.
The frequency that patients were screened impacted the reliability of the measure. The
rates of documentation of screening for lavender contraindication in the EMR aromatherapy
documentation reports ranged from 16.7% to 50.0% of surgical-orthopedic unit patients weekly.
During the four Rounding for Results sessions, 38 of 78 patients, 49%, were potential users of
aromatherapy, because they were not cognitively impaired and could verbalize agreement to use
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the aromatherapy, which was a required element in the hospital policy. Only nine of these 38
patients, 23.7%, were observed to have screening for contraindication documented. One patient
was screened but did not receive education. Eight patients had documentation of an offer for
aromatherapy and the other patient who was offered but declined did not have this documented.
Nurses were often engaged in other patient care activities during the Rounding for
Results sessions, which did not allow time for them to be directly mentored by the DNP student.
Nurses were willing to offer aromatherapy and indicated they would assess the patients later in
the shift. Based on the EMR data during that same four-week period, 24 of 25 patients with no
documentation of contraindication received aromatherapy as compared to eight patients during
the Rounding for Results sessions. These data confirm that nurses screened and offered patients
aromatherapy outside of the Rounding for Results sessions.
Logic Model Outcomes
Logic model outcomes data are reported in Appendix W.
Short-term outcome results.
The first short-term outcome was that surgical-orthopedic unit clinical nurses, nurse PCs,
and other clinicians would articulate lavender aromatherapy benefits, the patient assessment
protocol, and key points for patient education demonstrated by a score of at least 80% on the 15minute computer-based aromatherapy learning module post-test. This outcome was met for all
surgical-orthopedic unit clinical nurses because all 24 successfully completed the post-test. The
outcome was met for all four nurse PCs who verbally indicated they completed the module.
However, the verbal reports could not be validated with queries by name, since the learning
management system report was de-identified. It was not possible to determine the percentage of
all clinicians who completed the module. In addition to the surgical-orthopedic clinical nurses,
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an additional 305 community hospital associates successfully completed the module for a total of
329 associates: 225 clinical nurses practicing in direct care, 32 certified nursing assistants, 18
nurse leaders, 12 technicians, 11 non-direct care nurses, 10 unit-secretaries, eight physicians’
assistants/surgical assistants five transporters, three advanced practice registered nurses, two
nurse educators, two licensed practical nurses and one physician.
The second short-term outcome measured the intent of surgical-orthopedic unit clinical
nurses to offer lavender inhalers to patients. The target for this outcome was 100% of surgicalorthopedic unit nurses would verbalize intent to offer lavender during DNP student weekly
Rounding for Results. This outcome was not met but was nearly achieved. During the first three
of four weekly Rounding for Results sessions, all nurses on duty articulated to the DNP student
their intent to offer lavender aromatherapy inhalers to patients. On the final week, five of the six
nurses on duty also indicated intent to offer lavender aromatherapy inhalers to patients. The
remaining nurse was very busy caring for several complex patients. The nurse understandably
commented that providing aromatherapy was not a priority and she did not have time to discuss
aromatherapy at all. In summary, in 22 of 23 encounters, 96% of the time, nurses indicated
intent to offer lavender aromatherapy inhalers.
The third short-term outcome was surgical-orthopedic unit clinical nurses would
demonstrate the skill to appropriately use and teach patients to use lavender inhalers measured by
observation of surgical-orthopedic patient use of the inhalers. The target for this outcome was
100% of surgical-orthopedic unit patients who received inhalers would demonstrate correct use
by the end of the fourth week of the DNP Rounding for Results sessions. This outcome was not
met. Only three of eight patients, 37.5%, demonstrated and verbalized correct use. On weeks
one, two, and three, 50% of patients, one per week, correctly verbalized and demonstrated use,
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and on week four neither patient of the two patients verbalized and demonstrated correct use.
All patients were given written instructions that the nurses verbally reviewed with them. The
written instructions were at a fifth-grade reading level and were vetted by a health literacy
expert. Of the five patients who required re-education on lavender aromatherapy inhaler use, all
misunderstood the frequency of use. The inhaler can be used up to four times per hours. Four
patients stated it could be used only every four hours and one stated every six hours. No patients
were observed to use the device in an unsafe manner; one patient was unsure how near to the
nose to hold the inhaler. Several of these patients had recently been admitted to the unit and
some were in the immediate post-operative period, which may have limited understanding of the
instructions.
The fourth short-term outcome was surgical-orthopedic unit nurse leaders would establish
recommended par levels of lavender inhaler. The target for this outcome was each week during
DNP Rounding for Results sessions, the number of lavender inhalers would be observed to be at
par level for the day in the unit’s supply rooms. This outcome was met. On all four weeks the
DNP student observed inhalers were available in both supply rooms of the unit. Nurse leaders
established recommended par levels of lavender inhalers initially at five inhalers per supply
room and on the second week increased the number to 10 inhalers per supply room. At the time
of the Rounding for Results sessions, which occurred in the afternoon hours each week, the
number of inhalers in the supply room bins ranged from three to 10. Accounting for inhalers
placed in use earlier in the day, the par levels were adequate.
The fifth short-term outcome was that the surgical-orthopedic unit nurse leaders would
verbally report to the DNP student that they mentioned lavender aromatherapy inhalers to the
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patients during nurse leader patient rounds on all four weeks of the Rounding for Results
sessions. This outcome was met.
Medium-term outcome results.
The first medium-term outcome was surgical-orthopedic patients would be screened for
aromatherapy during the first four weeks of the project. The target for this outcome was 20% of
adult surgical-orthopedic unit patients during week one of the project, increasing by 20%
increments each week of the Rounding for Results sessions, to 80% on week four. This outcome
was measured by observations of documentation during the Rounding for Results sessions and
the EMR aromatherapy documentation reports.
In the Rounding for Results sessions, the target was not met on any of the four weeks. In
all four weeks combined only nine of 38 patients, 23.7%, who could have potentially benefited
from lavender aromatherapy were screened at the time of the Rounding for Results sessions.
Screening ranged from 16.7% of patients on the first and second weeks to 50% of patients on
third week to 25% of patients on fourth week. Patients were excluded if they did not report pain
or if their cognitive status prevented education about aromatherapy or the ability to verbally
agree to use aromatherapy. Barriers observed during Rounding for Results sessions included: (a)
a patient having nausea at the time of rounds; (b) lack of documented pain assessment; (c)
nurses’ decisions not to document the aromatherapy assessment when patients declined to use it;
(d) one nurse’s misperception that lavender aromatherapy was limited to only post-operative
orthopedic procedure patients, despite the policy to offer to all patients having pain; (e) travel
nurses’ lack of awareness of lavender aromatherapy because they were not provided the lavender
aromatherapy computer-based training and did not attend the Lunch & Learn presentations; (f)
nurses’ difficulty finding the lavender aromatherapy inhalers in the supply room until shown the
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location by the DNP student; and (g) nurses stated-bias that patients receiving opioids would
decline the lavender aromatherapy, so they did not ask these patients. The nurse who thought
lavender aromatherapy was limited to only post-operative orthopedic procedure patients
misunderstood a nurse leader who asked that nurses focus on this group of patients. The nurse
leader had not intended her comment to exclude other patients having pain. Eight patients
reported pain on previous days when lavender aromatherapy should have been considered but
their pain resolved at the time of the Rounding for Results session; these patients were included
in the denominator.
In the weekly EMR aromatherapy documentation reports, the target was only met on the
first week when 25% of patients had documentation of screening and the target was 20%, the
lowest of the four weekly targets. In all four weeks combined only 25 of 149 patients, 16.7%,
who were admitted to the unit had documentation of screening. Screening ranged from 3.1% of
surgical-orthopedic unit patients on the fourth week to 26.7% patients on the third week.
However, the surgical-orthopedic unit screened more patients that the other six inpatient
units combined. Over this same four-week period, only 34 of 4,112 patients on all seven
inpatient units, including the surgical-orthopedic unit patients, had documentation of screening
for aromatherapy. This was less than one percent of patients compared with 16.7% of patients
admitted to the surgical-orthopedic unit. These 34 surgical-orthopedic unit patients constituted
61% of all community hospital patients screened for aromatherapy. The comparison of weekly
percentages of patients screened for lavender aromatherapy on the surgical-orthopedic unit to all
inpatient units is provided in a run chart (Appendix X).
The second medium-term outcome was appropriate surgical-orthopedic patients would be
offered lavender aromatherapy during the first four weeks of the project. The target for this
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outcome was 20% of adult surgical-orthopedic unit patients during week one of the project,
increasing by 20% increments each week of the Rounding for Results sessions, to 80% on week
four. This outcome was measured by observations of documentation during the Rounding for
Results sessions and the weekly EMR aromatherapy documentation reports. To avoid placing
undue pressure on nurses or patients no target was set for percent of patients without a
contraindication who agreed to use the lavender inhaler.
In the Rounding for Results sessions, the target was met all four weeks. Documentation
of aromatherapy offer was observed in eight of the nine patients, 88.89%, who were screened
over the four-week period.
In the weekly lavender aromatherapy EMR reports, the target was met three of four
weeks: Documentation of aromatherapy offer was observed in 100% of patients who were
screened in the first, second, and fourth weeks and 92% of patients in the third week. In all four
weeks combined 24 of 25 patients, 96%, who were screened for aromatherapy were offered
aromatherapy. As previously discussed, there were likely more patients who were appropriate
for aromatherapy who were not screened. The frequency that patients were screened impacted
the reliability of the measure both in the Rounding for Results data and the electronic medical
reports data.
There was no target for percent of patients without a contraindication to agree to use the
lavender inhaler to avoid placing undue pressure on nurses or patients. The documentation data
in the weekly EMR aromatherapy documentation report indicated all 24 patients who were
screened and offered aromatherapy agreed to use it. This may be an overestimation of patient
agreement to use lavender aromatherapy because the DNP student observed during the Rounding
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for Results sessions that nurses did not consistently document the aromatherapy assessment
when patients declined.
The third medium-term outcome was self-administration of the lavender inhalers as
intended, measured by observations of patient use during each weekly Rounding for Results
session. The target that all surgical-orthopedic unit patients who received inhalers would
demonstrate correct use was not met on any of the four weeks. Only three of eight patients,
37.5%, demonstrated and verbalized correct use. Additional discussion of this outcome is
located on pages 45-46.
Long-term outcome results.
The long-term outcome of well-managed patient pain experience was met, evidenced by
surgical-orthopedic unit pain management experience scores at or above the NRC Picker
database average score for Magnet hospitals by the end of the third quarter of FY 2019. As
noted on in the evaluation of the primary clinical question on page 42, the surgical-orthopedic
unit patient pain management experience improved by 35 percentile ranks during the
implementation period. Before implementation, the surgical-orthopedic unit scores were below
target. In the first quarter, the scores were 52.2% positive, ranking in the 12th percentile as
compared to Magnet hospitals in the NRC Picker data base. In the second quarter, the scores
were 63.0 % positive, ranking in the 43rd percentile, but the second quarter scores reliability was
limited by a small sample size. In the third quarter, during implementation of lavender
aromatherapy, the surgical-orthopedic unit score increased to 72.2 percent positive ranking at the
78th percentile.
Before implementation, the community hospital scores were below target in the first
quarter at 59.3% positive, ranking in the 31st percentile, and above target in the second quarter at
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63.3 % positive, ranking in the 56th percentile. After implementation in the third quarter, the
community hospital score decreased below target at 64.1% positive, ranking at the 46th
percentile, although the score itself increased. While the surgical-orthopedic unit scores
increased 35 percentile ranks during implementation, the community hospital scores decreased
10 percentile ranks.
The second long-term outcome that all appropriate surgical-orthopedic unit patients were
offered lavender inhalers during weeks five and six of the project was met. This outcome was
measured by the weekly EMR aromatherapy report. Weeks five and six occurred after the
Rounding for Results Sessions were finished. Appropriate patients were defined as those with
documentation of screening and no contraindication to lavender aromatherapy. The outcome
denominator included only the nine patients with documentation of screening as compared to the
71 patients admitted to the unit during those two weeks including: seven of 41 patients, 17.5%,
admitted the fifth week and two of 31 patients, 6.5%, admitted the sixth week. All nine of the
patients had documentation that they verbally agreed to use lavender aromatherapy. In the six
weeks of the project combined, only 34 of 220 surgical-orthopedic unit patients, 16%, had
documented screening. The effectiveness of this measure relied on patients being screened and
this screening documented. As discussed previously, the frequency that patients were screened
impacted the reliability of the measure.
Use of lavender aromatherapy was also measured indirectly through monthly supply
chain consumption reports of lavender inhalers. Consumption was compared to the number of
patients with documented agreement to use an inhaler. In February and March on the surgicalorthopedic unit, 144 inhalers were consumed as compared with only 33 patients who were
documented as agreeing to use an inhaler. During this same time on all inpatient units, including
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the surgical orthopedic unit, 419 inhalers were consumed as compared with 55 patients who were
documented as agreeing to use the inhalers.
Possible reasons for the discrepancy between inhaler consumption and the number of
patients documented as agreeing to use an inhaler were: (a) patients used more than one inhaler,
which was noted on more than one occasion when a nurse did not realize the patient already had
one; (b) inhaler use was not documented because some nurses indicated they were not sure
where to document but provided the inhaler; and (c) inhalers were removed by clinicians but not
given to the patients. The inhalers were a non-charge item and could be removed by anyone with
access to the supply room.
In the month following the project, inhaler consumption increased in both the surgicalorthopedic unit and all inpatient units combined. The surgical-orthopedic unit monthly inhaler
consumption was 69 the first month, 75 the second month, and 79 the month after the project.
The combined inpatient inhaler consumption was 207 the first month, 212 the second month, and
250 the month after the project. Over the three-month period, the surgical-orthopedic unit
consumed 33% of the inhalers purchased by the community hospital inhalers, while the unit’s
patient volume was only 3.5% of hospital inpatient admissions.
Discussion
Implications for Practice
The change agent strategy of Rounding for Results and Lunch & Learn sessions on the
surgical-orthopedic unit was feasible and effective. The surgical-orthopedic unit implemented a
disproportionate majority, 61%, of the community hospital’s documented screenings for
aromatherapy and was responsible for 33% of the hospital’s consumption of lavender inhalers,
despite only admitting 3.5% percent of all inpatients. Surgical-orthopedic unit pain experience
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scores increased by 35 percentile ranks and met the Magnet hospital average target during
implementation, while the community hospital overall decreased by 10 percentile ranks and did
not meet the Magnet hospital average target.
The DNP student change agent had the opportunity to identify and mitigate point of care
barriers that are often unforeseen in the project planning stage. In this project, the DNP student
mitigated the barriers observed in the Rounding for Results sessions as follows: (a) assisted
nurses with locating the inhalers; (b) communicated the difficulty locating inhalers to the nurse
leaders, who then assisted nurses on all shifts to find them; (c) identified travel nurses had not
completed the computer-based module and communicated this to the nurse educator, who then
corrected the learning plan for travel nurses; and (d) observed nurses’ bias that patients who were
receiving opioids would not want to try the lavender aromatherapy and addressed it by role
modeling the discussion with these patients at the bedside and communicating aromatherapy
patient success stories to the nurses.
In addition to the computer-based learning module that was completed by nurses in all
health system hospitals, the surgical-orthopedic unit nurses received: (a) Lunch & Learn sessions
attended by 14 of the 24 nurses; (b) real-time coaching by the DNP student during four Rounding
for Results sessions; and (c) aromatherapy huddles provided by the unit nurse PC in provided to
multiple shifts during the project. Despite the enhanced education and coaching, the adoption of
the practice change of lavender aromatherapy was slower than anticipated. Computer-based
modules provided basic knowledge for the practice change, while point-of-care rounding
provided reminders, role modeling, and information clarification. Point-of-care rounding
facilitated commitment, action and adoption of the change, but not as rapidly as expected.
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The impact of the change agent strategy of unit-based pain champions was limited in this
project for several reasons: (a) only four of the seven units were represented at the nurse PC
program meetings when aromatherapy was discussed; (b) the nurse PC program was new and the
aromatherapy discussions occurred just after inception, in the programs’ second and third
meetings; and (c) aromatherapy was the first project implemented by the nurse PCs. Transition to
new nursing roles often take at least one year (Gunnarsdottir et al., 2017). Several nurse PCs
indicated initial hesitancy to discuss practice change with peers and uncertainty as to how to
conduct unit-based huddles to promote aromatherapy. The four nurse PCs overcame these
challenges and reported promoting aromatherapy on their units through huddles and/or peer
coaching.
Implications for Healthcare Policy
DNPs possess the knowledge, skills and attitudes required to act as change agents to
foster action and adoption and sustainment and integration of EBP (Kleinpell, 2014). This
project required DNP competencies for: (a) location, appraisal and synthesis of evidence; (b)
project development and execution through a logic model; (c) incorporation of the Iowa model
dissemination strategy of change agents; (d) utilization of EMR documentation data; (e) patient
advocacy; and (e) advanced practice mentorship of clinical nurses (American Association of
Colleges of Nursing [AACN], 2006; Taylor-Powell et al., 2003). Funding is needed to develop
high-quality research to measure the impact of the DNP role on EBP implementation (Kleinpell,
2014). For example, the review of the literature, spanning over 25 years, regarding the nurse PC
role revealed: (a) only one randomized controlled trial that was conducted in Iceland, and (b) 15
observational and qualitative studies from Australia, Canada, China, and the United States (Allen
et al., 2018; Eaton et al., 2013; Ferrell et al., 1993; Grant et al., 2011; Greenway & Corston,
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2016; Gunnarsdottir et al., 2017; Holley et al., 2005; Kaasalainen et al., 2015; Ladak et al., 2013;
McCleary et al., 2004; McMillan, Tittle, Hagan, & Small, 2005; Overstreet, 2012; Paice et al.,
2006; Telford, Nichols, & Watson, 2019; Tong et al., 2019). Additional high-quality nurse PC
research studies are needed to identify key interventions for nurse PCs and DNP/APRN mentors
and demonstrate clinical outcomes.
The challenge of funding nurse PC programs was described across geographic locations,
settings of community hospitals and academic medical center, and throughout the 25-year
timespan of the literature (Allen et al., 2018; Grant et al., 2011; Gunnarsdottir et al., 2017; Ladak
et al., 2013; McCleary et al., 2004; McMillan, Tittle, Hagan, & Small, 2005; Tong et al., 2019).
Nurse PCs require funding to advance their subject matter expertise through educational
conference attendance, meet as a community of practice, and do the work of improving practice
by conducting unit-based education, rounds, and quality improvement projects. Policy is needed
to promote, fund, and recognize the resources required to implement and sustain this role.
Implications for Executive Leadership
The role of executive leadership in change initiatives includes: (a) evaluating if the
proposed initiative is likely to create excellence; (b) identifying and securing the resources
required for the initiative to achieve excellence; (c) communicating the requirements to key
stakeholders from other disciplines and within nursing, including clinical nurses, unit nursing
leaders, nursing informatics specialists, nursing practice specialists, nursing quality specialists,
and nursing professional development specialists; and (d) setting a cadence for data-driven
reporting of initiative milestones and impact to key stakeholders (McBride, 2011) . The
community hospital CNO evaluated the potential of the project to improve patient pain
experience that was an organizational priority with both reputational and financial impact for the
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hospital. The CNO communicated her support to: (a) the hospital President and the Vice
President for Medical Affairs; (b) the senior director for nursing who engaged unit managers,
nurse educators, and the supply chain leader to support the initiative; and (c) all associates, by
authoring a hospital newsletter article in collaboration with the DNP student. The CNO also
invited the DNP student to present the project overview including information about lavender
aromatherapy and the role of the DNP student and nurse PC change agents to the hospital Patient
and Family Quality and Safety Council. The surgical-orthopedic unit nurse manager supported
the initiative by: (a) attending one of the Lunch & Learn sessions to show support; (b) ensuring
that lavender aromatherapy was included in nurse leader rounds with patients, which was
verbally validated each week at the Rounding for Results sessions; and (c) reinforcing the
importance of lavender aromatherapy as part of her role as the hospital leader of the nurse PC
program.
Despite these key tactics, the adoption of the practice change was slower than anticipated,
even on the surgical-orthopedic unit. The project was structured with a six-week timetable, a
logic model, and more educational and coaching interventions than typical for the community
hospital to include in a practice change project. The logic model addressed anticipated
challenges but did not identify all challenges encountered, including the slower than expected
adoption of the practice change. The experience of slow and complex practice change was
consistent with the findings of a survey of CNOs: 44% did not feel EBP could be implemented in
timely manner and half were unsure of the steps required for a successful practice change
(Melnyk et al., 2016). Based on Rounding for Results sessions observations by the DNP student,
the community hospital CNO requested additional rounds by the hospital’s CNS and nurse
educators to assist clinical nurses on all units in locating the lavender inhalers and documenting
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aromatherapy. Like the community hospital CNO, executive leaders may need to fortify practice
change with additional resources.
Implications for Quality/Safety
Most patients who agreed to use it lavender aromatherapy did not understand the
frequency correctly, despite receiving education. These patients thought aromatherapy could
only be used hours apart instead of four times an hour, which could have limited the impact for
pain management. The patient education material had been vetted with a health literacy expert
for readability, was fifth grade level, and was only one page in length. However, patient
readiness to learn was limited because patients often had undergone a surgical procedure or had
just arrived on the surgical-orthopedic unit. Use of the teach-back technique, for bi-directional
communication between patient and nurse, had been promoted by the community hospital’s
health system (Brown, Mack, Guzetta, & Tefera, 2014). However, based on the observations of
these patients, clinical nurses may not have been comfortable or felt they had time to use teachback as part of the patient education process. Evaluation of the effectiveness of lavender
aromatherapy education effectiveness was required to achieve quality and safety.
Development and utilization of EMR reports was another feature of this project. The
EMR aromatherapy documentation report was designed to measure the frequency of patient
screening and offers of aromatherapy. However, without establishment of benchmarks for the
percentage of patients who were candidates for aromatherapy, the report’s meaning to nurse
leaders was limited. Based on the Rounding for Results observations, a recommendation was
made to limit the patient denominator to only those with pain to improve its usefulness. The
comparison of the supply chain data to the EMR reports revealed lavender aromatherapy
documentation did not match actual patient use. This was shared with nurse PCs who worked to
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foster accurate documentation on their units. EMR reports were a useful tool to evaluate the
practice change but required point-of-care validation to ensure quality.
Although patient allergic reaction to lavender aromatherapy is rare, one patient observed
in the Rounding for Results session verbalized a pre-existing intolerance, so no lavender
aromatherapy inhaler was provided (Buckle, 2015). Intolerance screening as a component of
nurse-directed lavender aromatherapy was an important safety process.
Plans for Sustainability and Future Scholarship
The integration and sustainment strategy for lavender aromatherapy included a plan for
ongoing nurse PC unit activities: review of EMR aromatherapy documentation reports, review of
patient pain management experience scores, observation of patient aromatherapy use, audits of
EMR documentation, and educational huddles for peers. The hospital’s CNS planned to
continue to mentor the nurse PCs, monitor lavender aromatherapy documentation and patient
experience scores, and provide unit-based pain rounds that included promoting the use of
lavender aromatherapy. The community hospital’s nurse PC program was part of the health
system’s nurse PC program that included ongoing review of system-wide EMR aromatherapy
documentation reports and patient experience data, promotion of best practices for pain
management through nurse PC system meetings, and facilitation of monthly PC program leader
meetings. The hospital’s CNS was also a member of a system-wide committee of nursing
practice leaders that conducted ongoing review of system-wide EMR aromatherapy
documentation reports and patient experience data.
The Rounding for Results observations provided observations to improve the utility of
the EMR aromatherapy documentation reports. Once the reports capture the appropriate
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patients, a large observational study of aromatherapy effectiveness of similar design to the study
conducted by Johnson and colleagues (2016) could be completed.
The frequency and dose of opioid medication use in patients receiving lavender
aromatherapy from EMR data is another outcome of interest for future scholarship. Although
decreases in pain intensity and opioid medication use in patients who receive aromatherapy were
reported in the literature, these outcomes were not measured in this project. One nurse PC
anecdotally reported a patient decided to use the lavender aromatherapy during the day and
opioids only at night to decrease pain to sleep. The patient expressed effective pain management
with this approach.
The community hospital planned to engage nurse PCs in future implementation of TENS
as another NPPMI. The TENS implementation planning included the methodology of this EBP
study: a logic model, the Iowa model strategy of nurse PCs, and electronic medical reports to
measure documentation and prevalence of use.
Conclusion
The intervention of engaging change agents was effective in achieving implementation of
nurse-directed lavender aromatherapy to improve pain management experience in adult patients
on a surgical-orthopedic unit of a community hospital. The surgical-orthopedic unit patient pain
management experience percentile ranking increased from the 43rd percentile the quarter before
implementation to the 78th percentile during the implementation period. The Lunch & Learn
presentations and Rounding for Results sessions impacted the extent of lavender aromatherapy
adoption evidenced by the surgical-orthopedic unit patients comprising 61% of all community
hospital patients screened for aromatherapy and 33% of the hospital’s lavender inhaler use. Use
of a logic model guided successful implementation. The strategies of Lunch & Learn
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presentations, Rounding for Results sessions, and nurse PC discussions were feasible. The
implementation of the nurse PC strategies of unit-huddles and peer coaching identified in the
nurse PC discussions was limited to four of seven hospital units. Adoption of the practice
change was slower than anticipated and required additional rounds by the hospital CNS and
nurse educators. Utilization of EMR aromatherapy documentation reports provided insight into
lavender aromatherapy use for all inpatients. Rounding for Results observations provided
insights for improvement of these EMR reports. The logic model methodology, interventions of
Lunch & Learn presentations, Rounding for Results sessions, and nurse PC-directed unit huddles
and peer coaching were suitable for implementation of future practice changes.
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Appendix A
Non-Pharmacological Pain Management Intervention Frequency in an Audit of 65 Patient Records
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Appendix B
Completed Project Plan for Health System Product Pilot of Lavender Aromatherapy
Process Steps
Legal Review
Aromatherapy Product
Approval
Supply processes
Patient and family education
document
Electronic medical record
documentation
Clinical Protocol including
physician subject matter
expert review.
Aromatherapy education
development for pilot
Occupational Health Review
Laundry Service Testing
Pilot of product and process

Dec.
2017

Jan.
2018

Feb.
2018

Mar.
2018

April May Jun. Jul.
2018 2018 2018 2018

Aug.
2018

Sep.
2018

Oct.
2018

Nov.
2018
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Appendix C
Health System Protocol for Lavender Aromatherapy for Pain Management
Definitions
•

Clinical aromatherapy: the use of oils that come from plants to improve how individuals feel
physically and emotionally with outcomes that are measurable. It is different than aesthetic
aromatherapy that is the use of oils for enjoyment.

•

Essential oils: plant derived oils that are extracted by distillation or extraction, which differs
from fragrance oils that are synthetic and are often used in perfumes.

•

Direct inhalation: delivery of the aroma of the essential oil via an impregnated carrier such as
an inhaler located near the patient. Direct inhalation differs from diffusion in which the
essential oil is dispersed through a room.

Target Population for Pain Management with Lavender Aromatherapy
•

The target population for lavender aromatherapy is adult patients, ages 18 and older,
experiencing acute or chronic pain or who have anticipated procedural pain. This includes
patients in inpatient, observation, emergency department or procedural settings.

•

Only patients who agree to use lavender aromatherapy should receive this intervention.

•

Although this product may be safely used in pediatric patients above the age of five, the
initial implementation will be limited to adults. Inclusion of pediatric patients may be
considered after successful implementation in the adult population.

Product Selected by Health System Nursing Product Evaluation and Standardization
Council (NPSEC)
•

Plant Extracts Aethereo®Sticks: an inhaler that the patient can hold and lasts for up to several
months
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Indications
•

Acute pain including post-operative pain and anticipated procedural pain.

•

Chronic pain, particularly neck and back pain.

Contraindication
•

Patient allergy or intolerance to the lavender plant or lavender essential oil.

Special Considerations
•

Avoid use of lavender aromatherapy when the patient is in contact with children under the
age of five. This includes post-partum mothers while in contact with the newborn. The Plant
Extracts Aethereo®Sticks inhaler should be closed when children under the age of five are in
the room.

•

If visitors or associates who are in direct contact with the patient have intolerance to lavender
aromatherapy, the Plant Extracts Aethereo®Sticks inhaler should be capped when those
individuals are in the room.

•

In a semi-private room, if the patient’s roommate has intolerance to lavender aromatherapy,
the Plant Extracts Aethereo®Sticks inhaler should be capped when the roommate is in the
room.

Parameters for Lavender Aromatherapy
•

Only nurses who have received education about lavender aromatherapy may administer it.

•

A provider order is not required for lavender aromatherapy.

•

Only direct inhalation via the Aethereo®Sticks inhaler will be used as the mode of delivery.
Diffusion will not be considered.
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Patient Assessment and Provision of Lavender Aromatherapy
•

The nurse will ask the patient if he/she would like to use lavender aromatherapy and obtain
patients’ verbal agreement prior to initiating its use.

•

The nurse may consider patients with decreased ability to smell for the intervention because
these patients may still benefit from aromatherapy.

•

The nurse will assess the patient for history of intolerance to the lavender plant or essential
oil.

•

In a semi-private room, the nurse will ask the patient’s roommate if she/he has intolerance to
lavender aromatherapy. If the roommate is intolerant, the nurse may use judgment to select
one of these actions: (a) advise the patient that the Plant Extracts Aethereo®Sticks inhaler
should be capped when the roommate is in the room; (b) make arrangements, if feasible, for a
room change to allow the aromatherapy without capping; or (c) stop the aromatherapy
assessment.

•

The nurse will complete a pain assessment with a valid pain scale before and within 60
minutes after initiation of lavender aromatherapy.

•

The nurse will review the patient and family education sheet for the product selected and
instruct to the patient in a guided relaxation or deep breathing exercise during the initial use
of the lavender aromatherapy. The education sheet may be printed from the aromatherapy
assessment in MedConnect EMR system or from the StarPort intranet site.
o

The nurse will provide the aromatherapy with Aethereo®Sticks inhaler
▪

Give the patient a lavender aromatherapy Aethereo®Sticks inhaler.

▪

Instruct the patient to take off the top and hold it three or four inches from the nose
and breathe in slowly.
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▪

Assess the patient for any immediate intolerance to the Aethereo®Sticks inhaler.

▪

Instruct the patient to do this as needed, but no more than four times an hour.

▪

Instruct the patient to close the inhaler tightly after use.

▪

Instruct the patient that the inhaler must be closed when near children under five.

▪

Instruct the patient that the Aethereo®Sticks inhaler is intended for eternal use only.
It is not to be placed in the mouth or nose.

Disposal
•

The Aethereo®Sticks inhaler product should be capped and disposed of in a waste receptacle.

Documentation
The following elements should be documented in the electronic medical record:
•

Presence or absence of lavender contraindication/reaction.

•

Patient/family education provided.

•

Verbal agreement obtained.

•

Aromatherapy indication: acute pain, anticipated procedural pain, chronic pain.

•

Aromatherapy product administered: Aethereo®Sticks Lavender Inhalation.

•

Patient-reported aromatherapy frequency: More than once per hour, Once per hour, Every 2
hours, Every 4 hours, Every 6 hours, Every 8 hours, Every 12 hours, Less than every 12
hours.

•

Pain assessment before and within 60 minutes after initiation of lavender aromatherapy.
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Safety and Adverse Reactions
•

Safety Information
o Lavender aromatherapy is safe to use for most adult patients.1
o There are no commonly reported side effects for direct inhalation of lavender
essential oil.
o Allina Health uses the Plant Extracts Aethereo®Sticks inhalers along with other
products and reports no serious adverse events in over 60,000 aromatherapy
applications in 13 hospitals and over 80 clinics and home care (J. Streeter, personal
communication, May 24, 2018).

•

Management of Patient Intolerance
o If a patient develops intolerance to the lavender aromatherapy, such as a headache or
nausea, the nurse caring for the patient will immediately remove and discard the
lavender aromatherapy product. The product should be capped and disposed in a
closed waste receptacle outside of the patient room, preferably the soiled utility room.
o The nurse will notify the physician or advanced practice clinician of the intolerance
and note it in the patient’s electronic medical record.

1

Not regulated by the U.S. Food & Drug Administration (FDA). The FDA has not evaluated this
statement. Aromatherapy is not intended to diagnose, treat, cure or prevent disease.

CHANGE AGENT IMPACT ON PAIN THROUGH AROMATHERAPY

76

References
Buckle, J. (Ed.). (2015). Clinical aromatherapy: Essential oils in healthcare (3rd ed.). St. Louis,
MO: Elsevier.
Johnson, J. R., Rivard, R. L., Griffin, K. H., Kolste, A. K., Joswiak, D., Kinney, M. E., & Dusek,
J. A. (2016). The effectiveness of nurse-delivered aromatherapy in an acute care setting.
Complementary Therapies in Medicine, 25, 64–169. doi:10.1016/j.ctim.2016.03.006
Joswiak, D., Kinney, M. E., Johnson, J. R., Kolste, A. K., Griffin, K. H., Rivard, R. L., & Dusek,
J. A. (2016). Development of a health system-based nurse-delivered aromatherapy
program. Journal of Nursing Administration, 46(4), 221-225.
doi:10.1097/NNA.0000000000000327
Lakhan, S. E., Sheafer, H., & Tepper, D. (2016). The effectiveness of aromatherapy in reducing
pain: A systematic review and meta-analysis. Pain Research and Treatment,
2016(8158693), 1-13. doi:10.1155/2016/8158693
Mack, K. (2016). Aromatherapy for pain management in hospitalized adults: Systematic review.
Unpublished manuscript.
Posadzki, P., Alotaibi, A., & Ernst, E. (2012). Adverse effects of aromatherapy: A systematic
review of case reports and case series. International Journal of Risk & Safety in
Medicine, 24, 147-161. doi:10.3233/JRS-2012-0568
Streeter, J. (2017, October). Clinical aromatherapy. Paper presented at the Allina Health Penny
George Institute for Health and Healing, St. Paul, MN.

CHANGE AGENT IMPACT ON PAIN THROUGH AROMATHERAPY
Appendix D
Patient and Family Aromatherapy Education Document

77

CHANGE AGENT IMPLEMENTATION OF AROMATHERAPY
Appendix E
Nursing Education on Lavender Aromatherapy: PowerPoint Slides

78

CHANGE AGENT IMPACT ON PAIN THROUGH AROMATHERAPY

79

CHANGE AGENT IMPACT ON PAIN THROUGH AROMATHERAPY

80

CHANGE AGENT IMPACT ON PAIN THROUGH AROMATHERAPY

81

CHANGE AGENT IMPLEMENTATION OF AROMATHERAPY

82

Appendix F
Lavender Aromatherapy Directions for Clinical Nurses
Patients with acute or chronic pain may be candidates for aromatherapy.
Product Name: Aethereo®Sticks Lavender Aromatherapy
Inform patients about aromatherapy and its role in their overall treatment plan and goals.
Inform patient that aromatherapy is not licensed by states or regulated by the FDA.
Give Lavender Aromatherapy patent education sheet to the patient.
Document lavender contraindications that patient or family provide. Do not administer.
Obtain patient verbal agreement if no contraindications.
Ascertain roommate intolerance to lavender direct accordingly (capping or room change).
Perform initial pain assessment upon initiation and document in MedConnect.
Patient Directions
•

Unscrew the top and hold the inhaler three or four inches from your nose.

•

Breathe in slowly. Repeat no more than four times an hour

•

Close tightly after use.

•

Store at room temperature.

Reassess and document pain score one hour after use of lavender inhalation.
If a patient develops intolerance to the lavender aromatherapy, such as a headache or
nausea, the nurse caring for the patient will immediately remove and discard the lavender
aromatherapy product. The product should be capped and disposed in a closed waste receptacle
outside of the patient room, preferably the soiled utility room.
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Appendix G
Nurse-Directed Lavender Administration for Pain Management:
An Overview for Physicians and Advanced Practice Clinicians
Situation: Nurses will begin offering adult patients experiencing pain lavender aromatherapy by
nasal inhalation, beginning Fall 2018.
Background Information regarding Nurse-directed Lavender Aromatherapy:
•

Registered nurses will offer lavender aromatherapy nasal inhalers to adult patients
experiencing pain. The inhaler contains a high-quality lavender essential oil.

•

A physician or advanced practice clinician (APC) order will not be required.

•

The nurse will assess the patient for intolerance to lavender then ask if the patient wants to
use lavender aromatherapy. The patient will be instructed to hold the inhaler under the nose
and take deep breaths to inhale the lavender aroma, up to four times an hour as needed.
Nurses will document use in. In semi-private rooms, nurses will also assess roommates for
intolerance before use can begin.

•

Lavender should not be used near children under 5 years of age. Patients will be instructed
to cap the inhaler while children or others who may be intolerant are nearby.

•

There is moderate level of evidence that lavender inhalation improves acute pain
management.
o Randomized controlled clinical trials demonstrated statistically significant decreases in
pain scores in the lavender inhalation group as compared to the controlled group
(Bagheri-Nesami, Espahbodi, Nikkhah, Shorofi, & Charati, 2014; Heidari Gorji et al.,
2015; Irmak Sapmaz et al., 2015; Karaman et al., 2016; Kim et al., 2007). Kim et al.
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(2006) demonstrated statistically better patient satisfaction with pain management
despite no statistically significant decreases in pain.
o Kim et al. (2007) reported patients who inhaled lavender had statistically less opioid
use than the control group (Kim et al., 2007).
o Johnson et al. (2016) reported a mean decrease of 3 points on a 0-10 pain scale.
•

Patients in most of the health system hospitals have not reported satisfaction with pain
management at the desired benchmark. Lavender aromatherapy is a nonpharmacological
pain management intervention that aligns with Joint Commission standards.

•

Lavender inhalation is safe for most patients to use.2
o Essential oils do not contain proteins that are associated with Type I hypersensitivity
reactions. Like any other compound, it is possible for patients to develop IgG
antibodies with exposure (J. Baraniuk, personal communication, May 23, 2018).
However, this has not been commonly reported (Buckle, 2015). Use has not been
associated with clinical worsening of asthma (Buckle, 2015).
o Seven clinical trials reported no serious patient events (Bagheri-Nesami, Espahbodi,
Nikkhah, Shorofi, & Charati, 2014; Heidari Gorji et al., 2015; Irmak Sapmaz et al.,
2015; Johnson et al., 2016; Karaman et al., 2016; Kim et al., 2006; Kim et al., 2007).
o Two health systems, Allina Health and New York Presbyterian, reported no serious
patient or associate safety events with use in multiple hospitals over multiple years
(Joswiak et al., 2016; J. Seley, personal communication, May 30, 2018).

2

Not regulated by the U.S. Food & Drug Administration (FDA). The FDA has not evaluated this statement.
Aromatherapy is not intended to diagnose, treat, cure or prevent disease.
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Assessment: Nurse-directed lavender inhalation aromatherapy will be offered to patients
experiencing pain.
Request: Physicians and APCs become informed about this intervention. Physicians or APCs
discuss concerns regarding use in specific patients with the clinical nurse caring for the patient.
For additional information contact: Karen Mack, MS, MBA, APRN, CCNS, ACNP-BC, Clinical
Practice Program Specialist, System Nursing.
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Appendix I
Aromatherapy Lunch & Learn Presentation Objectives and Agenda
Learning outcomes:
At the end of the Lunch & Learn session clinical nurses will:
1. State the indications for aromatherapy.
2. Identify the key steps in the aromatherapy appropriateness assessment.
3. Explain how patients should use the lavender inhalers.
4. Describe actions to take if a patient develops an intolerance to the lavender inhaler.

Agenda:
1. Introduction (5 minutes)
Note: These questions will reinforce content provided in the aromatherapy computer-based
module that some participants nurses will likely have completed before the session.
Using a multiple-choice question and answer group participation session, clinical nurses will
answer the following questions:
a.

What is lavender aromatherapy?
i.

A new paint color to enhance moods.

ii.

Non-pharmacological, intervention that uses lavender essential oil
absorbed through the olfactory system used to manage pain and improve
physical and emotional well-being.

iii.

A new product to improve the smell of the hospital linen.
Answer ii is correct.
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Which of the following does not a mechanism of action of lavender
aromatherapy?
i.

Alters the perception at the sub-cortical and cortical pleasure memory
centers of the brain.

ii.

Works via the nasal route to the limbic system via olfactory bulb or via the
pulmonary route with inhalation of volatile compounds.

iii.

Causes the release cortisol.
Answer iii is correct. It does not cause the release of cortisol but does
affect neurotransmitter receptors for dopamine, seratonin and
noradrenaline.

c.

True or false: Lavender aromatherapy requires a physician or advanced practice
provider order.
Answer “false” is correct. It is a nurse-directed intervention that requires
assessment of patient intolerance

d.

The target population for lavender aromatherapy is:
i.

All patients having acute or chronic pain or may be having painful
procedures.

ii.

Only patients 18 and older having acute or chronic pain or may be having
painful procedures.

iii.

All patients because it may be helpful for sleep or anxiety.
Answer ii is correct. Although lavender is helpful for sleep and anxiety,
the hospital policy limits use to those patients 18 and older who are having
pain.
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When do the lavender inhalers expire?
i.

Seven days after opening.

ii.

Twenty-four hours day after opening.

iii.

Twelve months after opening.

iv.

Three months after opening.
Answer iv is correct: Three months after opening. Discard any unopened
inhaler that is more than 12 months old.

2.

3.

Present content by reviewing two aromatherapy documents (5 minutes)
a.

Lavender Aromatherapy Directions for Clinical Nurses. See Appendix F.

b.

Aromatherapy Patient and Family Education document. See Appendix D.

Learning assessment: (3 minutes)
Using a group participation session, clinical nurses will answer the following questions:
a.

What are key points to highlight in educating patients?
i.

It can help patients manage pain, but it is not FDA regulated to treat pain.

ii.

To hold the inhaler three to four inches from the nose and breathe in
slowly.

iii.

Close the inhaler when near children under 5 or anyone who says the
smell makes them sick.

b.

Who can provide it to patients?
i.

c.

What are the contraindications to lavender aromatherapy?
i.

d.

Only registered nurses who have completed the computer-based module.

Any patient-reported allergy or intolerance to lavender essential oil.

What must a patient do before you provide the inhaler?

CHANGE AGENT IMPACT ON PAIN THROUGH AROMATHERAPY
i.
e.

Verbally agree to use it.

How long after the first lavender use do you reassess the patient’s pain intensity?
i.

4.
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Approximately one hour

Question and answer session (2 minutes)
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Appendix J
Nurse Pain Champion Meeting Aromatherapy Discussions
The nurse pain champions will:
•

Identify nurse champion role domains that align with aromatherapy implementation.

•

Discuss aromatherapy indications, contraindications, patient education

•

Describe the four stages of the Iowa model of evidence-based practice (EBP) and how each
relates to aromatherapy implementation using the Hospital Aromatherapy Implementation
Action Plan. See Appendix P.

•

Determine two Iowa model EBP actions each nurse PC will take to foster implementation of
aromatherapy on her/his nursing unit.

•

Review aromatherapy supply chain and electronic medical record report data at each
meeting.

•

Identify implementation successes, barriers, best practice and barrier solutions.

Meeting 1 Agenda (30 minutes)
•

Review:
o Lavender Aromatherapy Directions for Clinical Nurses. See Appendix F.
o Aromatherapy Patient and Family Education document. See Appendix D.

•

Review the Iowa model of EBP dissemination stages and strategies. See Appendix M.

•

Review the Hospital Aromatherapy Implementation Action Plan Iowa model strategies. See
Appendix P.

•

Discuss what Iowa model strategies will be effective options the can implement for
aromatherapy implementation and select two.

CHANGE AGENT IMPACT ON PAIN THROUGH AROMATHERAPY
•

93

Develop two specific, measurable, attainable, relevant, time-bound SMART goals for
aromatherapy to foster aromatherapy implementation with an action that each nurse PC will
take in the next 30 days.

•

Review aromatherapy supply chain and electronic medical record report data.

Meeting 2 Agenda (30 minutes)
•

Discuss the successes and any barriers noted regarding aromatherapy implementation on
her/his unit.

•

Identify best practices and solution barriers from the discussion.

•

Report the two Iowa model EBP actions each nurse PC took to foster implementation of
aromatherapy on her/his nursing unit.

•

Review aromatherapy supply chain and electronic medical record report data.
•

Discuss two actions each nurse PC will take to foster aromatherapy implementation in the
next 30 days. This may include follow-up on pervious SMART goals or development of
new SMART goals.

CHANGE AGENT IMPLEMENTATION OF AROMATHERAPY

94

Appendix K
DNP Student Surgical-Orthopedic Unit Rounding for Results Form
Week _______Date____________
Nurse leader validates mentioning aromatherapy on leader rounds Yes No
Aromatherapy par levels adequate Yes No
Nurses who provide verbal intent to offer lavender: _______
Number of nurses interviewed on rounds: ________
Case Lavender
Lavender
Lavender aromatherapy Patient
Barriers,
aromatherapy
aromatherapy
offer documented if no
demonstrates
facilitators and
contraindication
education documented contraindication and
correct use of
comments.
screening documented. if no contraindication. education complete.
lavender inhaler.
1
Yes No N/A*
Yes No N/A**
Yes No N/A**
Yes No N/A***
2
Yes No N/A*
Yes No N/A**
Yes No N/A**
Yes No N/A***
3
Yes No N/A*
Yes No N/A**
Yes No N/A**
Yes No N/A***
4
Yes No N/A*
Yes No N/A**
Yes No N/A**
Yes No N/A***
5
Yes No N/A*
Yes No N/A**
Yes No N/A**
Yes No N/A***
6
Yes No N/A*
Yes No N/A**
Yes No N/A**
Yes No N/A***
7
Yes No N/A*
Yes No N/A**
Yes No N/A**
Yes No N/A***
8
Yes No N/A*
Yes No N/A**
Yes No N/A**
Yes No N/A***
9
Yes No N/A*
Yes No N/A**
Yes No N/A**
Yes No N/A***
10
Yes No N/A*
Yes No N/A**
Yes No N/A**
Yes No N/A***
11
Yes No N/A*
Yes No N/A**
Yes No N/A**
Yes No N/A***
12
Yes No N/A*
Yes No N/A**
Yes No N/A**
Yes No N/A***
13
Yes No N/A*
Yes No N/A**
Yes No N/A**
Yes No N/A***
14
Yes No N/A*
Yes No N/A**
Yes No N/A**
Yes No N/A***
15
Yes No N/A*
Yes No N/A**
Yes No N/A**
Yes No N/A***
* Pain is not present or anticipated and/or patient is excluded due to cognitive impairment, pregnancy, or prisoner status.
** Contraindication to lavender present.
*** Contraindication to lavender present or patient declined.
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Appendix L
Literature Review of Aromatherapy Experimental Trials with Lavender Aromatherapy as a Pain Management Intervention
Citation

Study Design

Bagheri-

Research
Question
In a population

Dependent Variable Sample size
(or Outcome)
Self-reported pain
Both the

Results

The study was a

Independent
Variable(s)
Aromatherapy

Nesami

of end-stage

randomized

with lavender

using the Visual

experimental

significant

(2014)

renal disease

controlled clinical

diluted with

Analog Scale

and control

difference between

patients

trial with an

sweet almond

groups were

the AT and the CG

undergoing

experimental

oil as compared

comprised of

after three sessions

hemodialysis via

group (AT) and a

to sweet

46 patients

(p < .009). Both

needle

control group

almond oil

each.

groups also had a

cannulation of

(CG).

alone described

significantly

as placebo.

decreased pain

the access site, is

A statistically

aromatherapy

score after three

with lavender as

treatments as

compared to

compared with

placebo
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Variable(s)
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Dependent Variable Sample size
(or Outcome)

Results
baseline (p < .001 in

decreased

both groups).

reported pain?
Heidari

In a population

The study was a

Aromatherapy

Self-reported pain

Both the

A statistically

Gorji

of patients who

randomized

with lavender

using the Visual

experimental

significant

(2015)

have undergone

controlled clinical

and

Analog Scale

and control

difference between

cardiac surgery

trial with an

supplemental

groups were

the AT and the CG

with sternotomy,

experimental

oxygen as

comprised of

was noted at five,

is aromatherapy

group (AT) and a

compared to

25 patients

30, and 60-minute

with lavender

control group

supplemental

each.

intervals post

with

(CG).

oxygen alone

intervention as

supplemental

compared to the CG

oxygen as

who received

compared to

supplemental

supplemental

oxygen alone (p <
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Study Design
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Variable(s)
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Dependent Variable Sample size
(or Outcome)

Results
.001, p < .002, p <

associated with

.001 respectively).

decreased
reported pain?
Irmak

In a population

The study was a

Aromatherapy

Self-reported pain

Both the

A statistically

Sapmaz

of patients with

double blinded

with lavender

using the Visual

experimental

significant

(2015)

renal colic is

placebo controlled

as compared to

Analog Scale

and control

difference between

aromatherapy

clinical trial with

normal saline

groups were

the AT and the CG

with lavender

an experimental

placebo

comprised of

was noted at 30

and conventional

group (AT) and a

50 patients

minutes but not at

each.

10 minutes post

care as compared control group
to conventional

(CG).

intervention as

care alone

Randomization

compared to the CG

associated with

was described but

who received

did not meet Jadad

placebo (p =.022 at
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Research
Question
decreased

Study Design

Dependent Variable Sample size
(or Outcome)

Results

or McMaster

30 minutes, p = .152

reported pain?

criteria for

at 10 minutes).

randomization
(Effective Public
Health Practice
Project, 1998;
Jadad et al.,
1996).
Karaman In a population

The study was a

Aromatherapy

Self-reported pain

Both the

There was a

(2016)
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with lavender

and anxiety using the

experimental
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Visual Analog Scale

and control
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difference in self-
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satisfaction Likert
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reported pain and
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scale.

53 patients

anxiety in the AT
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surgery, is
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control group
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Dependent Variable Sample size
(or Outcome)
and due to

Results
to the control group

drop-out for

(p < .01 and p <

aromatherapy

protocol

.001 respectively).

with lavender

issues, 51 were

There was a

and as compared

included in

statistically

to water

intervention

significant higher

associated with

and 50 in

patient satisfaction

decreased

experimental

scores in the AT

reported PVC

group analysis.

group as compared

pain, anxiety and

to the CG group (p

higher patient

< .003).

satisfaction?
Kim

In a population

The study was a

Aromatherapy

Self-reported pain

Both the

Self-reported pain

(2006)

of patients who

randomized

with lavender

using the Numeric

experimental

and opioid analgesic

have undergone

controlled trial

and

Rating Scale and

and control

use did not vary
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Research
Question
breast biopsy
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Dependent Variable Sample size
(or Outcome)
total number of
groups were

Results

without blinding

Independent
Variable(s)
supplemental

surgery, is

with an

oxygen as

oxycodone

comprised of

between the AT

aromatherapy

experimental

compared to

acetaminophen

25 patients

group and CG

with lavender

group (AT) and a

supplemental

tablets administered.

each.

group and no p

with

control group

oxygen alone

supplemental

(CG). All

reported for either

oxygen as

enrolled patients

of these variables.

compared to

received skin

Pain control

supplemental

sensitivity tests

satisfaction was

oxygen alone

prior to surgery as

statistically

associated with

stipulated by the
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decreased

institutional

higher scores in the

reported pain,

review board.

AT group as

significantly

values were

decreased opioid

compared to the CG

analgesic use

group (p < .05).
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Study Design

Independent
Variable(s)

Dependent Variable Sample size
(or Outcome)

Results

patient pain
management
satisfaction?
Kim

In a population

The study was a

Aromatherapy

Primary outcome:

Both the

There was a

(2007)

of patients who

randomized

with lavender

total opioid

experimental

statistically

have undergone

controlled clinical

and

analgesics

and control

significant

laparoscopic

trial with an

supplemental

administered.

groups were

difference of lower

adjustable gastric experimental

oxygen as

Secondary outcomes: comprised of

opioid use amount

banding (LAGB)

group (AT) and a

compared to

Self-reported pain

27 patients

and numbers of

surgery, is

control group

supplemental

with a Numeric

each initially

patients requiring

aromatherapy

(CG). All enrolled

oxygen with

Rating Scale,

and there was

opioids in the AT

with lavender

patients received

unscented baby

sedation with the

one drop-out

group as compared

with

skin sensitivity

oil

Observer’s

for a protocol

to the CG group (p

supplemental

tests prior to

assessment of

< .04 and p < .007
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compared to
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institutional

administration of

weight were

baby oil

review board.

anti-hypertensives or
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supplemental
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in the AT group (p<

oxygen

recovery unit length

.05 for both). The

associated with

of stay in minutes.

AT groups sedation

AT group.

respectively). Body

decreased opioid

at discharge from

analgesic use?

the recovery unit
was significantly
lower than the
control group
(p<.05). There were
no statistically
significant
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Dependent Variable Sample size
(or Outcome)

Results
differences between
the two groups in
self-reported pain,
antiemetic or
antihypertensive
administration, or
time spent in the
recovery unit.
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Appendix M
Iowa Model Implementation Strategies

Used/reprinted with permission from the University of Iowa Hospitals and Clinics, copyright
2012. For permission to use or reproduce, please contact the University of Iowa Hospitals and
Clinics at 319-384-9098.
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Aromatherapy Logic Model

105

CHANGE AGENT IMPLEMENTATION OF AROMATHERAPY

106

Appendix O
Weekly EMR System Aromatherapy Documentation Reports
•

Percent of patients with lavender aromatherapy contraindication screening documented.
o Numerator: Number of adult (age 18 or older) surgical-orthopedic unit patients with
Lavender Contraindication/Reaction field documented as “Yes” or “No.”
o Denominator: Number of adult (age 18 or older) surgical-orthopedic unit patients.

•

Percent of screened patients with lavender aromatherapy contraindication documented as
“Yes.”
o Numerator: Number of adult (age 18 or older) surgical-orthopedic unit patients with
Lavender Contraindication/Reaction field documented as “Yes.”
o Denominator: Number of adult (age 18 or older) surgical-orthopedic unit patients with
Lavender Contraindication/Reaction field documented as “Yes” or “No.”

•

Percent of screened patients with lavender aromatherapy contraindication documented as
“No” and lavender aromatherapy inhaler offer documented as “Yes” or “No.”
o Numerator: Number of adult (age 18 or older) surgical-orthopedic unit patients with
Lavender Contraindication/Reaction field documented as “No” and the Verbal
Agreement field documented as “Yes” or “No.”
o Denominator: Number of adult (age 18 or older) surgical-orthopedic unit patients with
Lavender Contraindication/Reaction field documented as “No.”

•

Percent of screened patients with lavender aromatherapy contraindication documented as
“No” and lavender aromatherapy inhaler offer documented as “Yes.”
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o Numerator: Number of adult (age 18 or older) surgical-orthopedic unit patients with
Lavender Contraindication/Reaction field documented as “No” and the Verbal
Agreement field documented as “Yes.”
o Denominator: Number of adult (age 18 or older) surgical-orthopedic unit patients with
Lavender Contraindication/Reaction field documented as “No.”
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Appendix P
Community Hospital Aromatherapy Implementation Action Plan
Tactic

Iowa Model Stages and
Levels
1. Encouragement of nurses to complete Interest & Awareness
an aromatherapy computer-based
Knowledge &
training module during the following Commitment
interactions: nurse PC meetings,
Key Stakeholder Level
Lunch & Learn presentations, and
Rounding for Results sessions.

Implementation
timeline
By the end of the
fourth week of DNP
student Rounding for
Results sessions.

2. Two nurse PC meeting discussions
Interest & Awareness.
about how to promote aromatherapy in Knowledge &
the practice setting.
Commitment, Action &
Adoption; Integration &
Sustainment
Key Stakeholder Level,
Organizational Level
3. Three Lunch & Learn aromatherapy
Interest & Awareness
presentations for surgical-orthopedic Knowledge &
unit clinical nurses.
Commitment
Key Stakeholder Level
4. Four DNP Rounding for Results
Interest & Awareness,
sessions with clinical nurses on the
Knowledge &
surgical-orthopedic unit.
Commitment, Action &
Adoption;
Key Stakeholder Level
5. Development of reports including
Action & Adoption;
supply chain monthly lavender inhaler Integration &
usage and EMR aromatherapy
Sustainment
documentation report for nurse PCs to Organizational level
review at their meetings.

By the end of quarter
three FY 2019.

By the end of the
fourth week of DNP
student Rounding for
Results sessions.
By the end of quarter
three FY 2019.

By the end of the third
quarter of FY 2019.
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Appendix Q
Aromatherapy Project Results Excel Workbook
Worksheet 1

Worksheet 2
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Worksheet 3

Worksheet 4
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Worksheet 5

Worksheet 6

Worksheet 7
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Worksheet 9
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Appendix R
Data Analysis Plan for Project Primary Clinical Question
“Was the strategy of change agents effective in achieving implementation of nurse-directed lavender aromatherapy to improve pain
management experience in adult patients on a surgical-orthopedic unit of a community hospital?”
Variable Type Measure
Data Source
Population
Measure Formula
Level of
Data
Description
Measurement
Analysis
Plan
Intervention
Bundle of three
(See below)
(See below)
Bundle: Complete/
Nominal for
Report
change agent
Not Complete
the Bundle
bundle was
(Independent) strategies (See
met.
below)
Strategy Sessions
Ratio
Values only
held by type
Strategy #1
Lunch & Learn Adult* surgical1. Number of
1. Ratio
1. Mean,
Three DNP
Excel
orthopedic unit
attendees per
Range
Student-led
worksheet
nurses and nursing
session and total
Lunch & Learns
associates
2. Number of
2. Ratio
2. Range
attendees by role
among
at all three
roles
sessions
combined
Strategy #2
Rounding for
Adult* surgicalNumber of patients
Ratio
Mean, Range
Four DNP
Results Excel
orthopedic unit
rounded on per
student-led
worksheet
patients
session
weekly
Rounding for
Results sessions
Strategy #3
Pain Champion Nurse pain
Number of pain
Ratio
Mean, Range
Two pain
program
champions (all
champions per
champion
meeting
units)
discussion
discussions
minutes
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Data Analysis Plan for Project Primary Clinical Question
“Was the strategy of change agents effective in achieving implementation of nurse-directed lavender aromatherapy to improve pain
management experience in adult patients on a surgical-orthopedic unit of a community hospital?”
Variable Type Measure
Data Source
Population
Measure Formula
Level of
Data
Description
Measurement
Analysis
Plan
Outcome
SurgicalNRC Picker
Adult* surgicalPercentage:
Ratio
Range of
(Dependent)
orthopedic unit
database
orthopedic unit
Numerator: Number
quarterly
adult patient pain
inpatients and adult of patients answering
percentage
management
hospital inpatients
the question
surgicalexperience for
completing the
“always”
orthopedic
fiscal year (FY)
NRC picker
Denominator:
unit scores,
2019 quarters
telephone survey
Number of patients
hospital
one through three
answering the
scores and
quarterly
question
Magnet
percentage
comparison
scores and
scores
Magnet hospital
comparison
Percentile:
Interval
Range of
percentiles for
Rank of unit and
quarterly
the question
hospital percentage
Magnet
“During this
score as compared to
percentiles
hospital stay,
Magnet hospitals in
for surgicalhow often did
the NRC picker
orthopedic
hospital staff talk
database
unit and
with you about
hospital
how to treat your
pain?” will
determine if after
the intervention
the Surgicalorthopedic Unit
exceeded the
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Data Analysis Plan for Project Primary Clinical Question
“Was the strategy of change agents effective in achieving implementation of nurse-directed lavender aromatherapy to improve pain
management experience in adult patients on a surgical-orthopedic unit of a community hospital?”
Variable Type Measure
Data Source
Population
Measure Formula
Level of
Data
Description
Measurement
Analysis
Plan
Outcome
average score
(Dependent)
and 50th
continued
percentile of
Magnet hospitals
in the NRC
Picker database
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Appendix S
Data Analysis Plan for Project Aims
Aim #1 To increase the surgical-orthopedic unit patient HCAHPS pain management experience score to equal or above the Magnet
average of hospitals in the NRC Picker database by the end of the third quarter of FY 2019.
Variable
Measure Description
Data Source Population
Measure Formula
Level of
Data
Type
Measurement Analysis
Plan
Outcome
Surgical-orthopedic unit NRC Picker Adult* surgicalPercentage:
Ratio
Mean,
Aim #1
adult patient pain
database
orthopedic unit
Numerator: Number
range of
(Dependent)
management experience
patients
of patients answering
quarterly
quarterly percentage
completing the
the question “always”
percentage
scores and Magnet
NRC picker
Denominator:
scores
hospital comparison
telephone survey
Number of patients
percentiles for the
answering the
question “During this
question
hospital stay, how often
did hospital staff talk
Percentile:
Interval
Range of
with you about how to
Rank of percentage
quarterly
treat your pain?”
score as compared to
percentile
Magnet hospitals in
scores
the NRC picker
database
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Data Analysis Plan for Project Aims
Aim #2 To achieve a consistent practice of 100 % of appropriate patients being offered lavender aromatherapy by the end of the
third quarter of FY 2019.
Variable
Measure Description
Data Source Population
Measure Formula
Level of
Data
Type
Measurement Analysis
Plan
Outcome
The number of surgical- Weekly
Adult* surgicalNumerator:
Ratio
Mean,
Aim #2a
orthopedic unit patients MedConnect orthopedic unit
The number of
range of
(Independent) documented to have no
EMR Report patients with
patients documented
weekly
contraindication to
aromatherapy
to have responded
percentage
lavender aromatherapy
documentation in “no” to lavender
scores
and who received an
the MedConnect
aromatherapy
offer of lavender
EMR database
contraindication and
aromatherapy reported
documented as
on a weekly basis for the
verbally responding
four weeks of the
either “yes” or “no”
project and two weeks
to an offer of
after the project based
lavender
on weekly electronic
aromatherapy
medical record (EMR)
documentation (each
Denominator:
week= 7 days of patient
The number of
data)
patients documented
to have responded
“no” to lavender
aromatherapy
contraindication
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Data Analysis Plan for Project Aims
Aim #2 To achieve a consistent practice of 100 % of appropriate patients being offered lavender aromatherapy by the end of the
third quarter of FY 2019.
Variable
Measure Description
Data Source Population
Measure Formula
Level of
Data
Type
Measurement Analysis
Plan
Outcome
The number of surgical- Rounding for Adult* surgicalNumerator:
Ratio
Mean,
Aim #2b
orthopedic unit patients Results
orthopedic unit
Number of
range of
(Independent) documented to have no
Excel
patients who were appropriate patients
weekly
contraindication to
worksheet
hospitalized
(documented pain
rounds
lavender aromatherapy
during the
and not cognitively
percentage
and who received an
Rounding for
impaired) with no
scores
offer of lavender
Results sessions,
lavender
aromatherapy reported
excluding
contraindication
on a weekly basis for the
prisoners and
documented and
four weeks of the
pregnant women
education complete
project based on
documented who
Rounding for Results
with a documented
weekly observation
offer of lavender
sessions (each week =
aromatherapy
one rounding session of
patient data on one day
Denominator:
during that week)
Number of
appropriate patients
(documented pain
and not cognitively
impaired) with no
lavender
contraindication
documented
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Appendix T
Data Analysis Plan for Logic Model Outcomes
Variable
Type
Logic Model
Short Term
Outcome
#1A
(Independent)

Measure
Description
Nurse PCs,
surgicalorthopedic unit
clinical nurses,
and other
clinicians can
articulate
lavender
aromatherapy
benefits, patient
assessment
protocol and
patient
education key
points as
demonstrated
by successful
completion with
a minimum
score of 80% on
the
Aromatherapy
SiTEL Learning
Management
System module

Data Source

Population

SiTEL
Learning
Management
System
Report

Surgicalorthopedic
unit clinical
nurses and
nurse PCs as
of 3/21/2019

All
community
hospital
clinicians
completing
the module as
of 3/21/2019

Measure
Formula
Numerator:
Number of
surgicalorthopedic unit
nurses
successfully
completing
module (score
of > 80%)/
Denominator:
Number
surgicalorthopedic unit
nurses
Descriptive data
only
Denominator
not available for
all community
hospital
clinicians

Level of
Measurement
Ratio

Data Analysis
Plan
N and
Percentage

Target

Ratio

N by unit and by No target for all
role
clinicians

100% of
surgicalorthopedic unit
nurses
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Data Analysis Plan for Logic Model Outcomes
Variable
Type
Logic Model
Short Term
Outcome #1B
(Independent)

Measure
Description
At each
Rounding for
Results session,
surgicalorthopedic unit
clinical nurses,
including nurse
PCs, articulate
intent to offer
lavender
inhalers to
patients
Logic Model At each
Short Term
Rounding for
Outcome #1C Results session,
(Independent) surgicalorthopedic unit
patients are
observed to
appropriately
use lavender
inhalers

Data Source

Population

Rounding
for Results
Excel
worksheet

Nurses
encountered
during
Rounding for
Results
Sessions on
the
orthopedicsurgical unit

Rounding
for Results
Excel
worksheet

Adult *
surgicalorthopedic
unit patients
who agreed to
use lavender

Measure
Formula
Numerator:
Nurses who
provide verbal
intent to offer
lavender

Level of
Measurement
Ratio

Data Analysis
Plan
Mean, range of
weekly
percentage
scores

Target

Ratio

Mean, range of
weekly
percentage
scores

100%

100%

Denominator:
Number of
nurses
interviewed on
rounds
Numerator:
Number of
patients who
agreed to use
lavender
aromatherapy
and who
correctly used
inhaler
Denominator:
Number of
patients who
agreed to use
lavender
aromatherapy
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Data Analysis Plan for Logic Model Outcomes
Variable
Type
Logic Model
Short Term
Outcome #2
(Independent)

Measure
Description
At each
Rounding for
Results session,
the number of
lavender
inhalers will be
observed to be
at par level for
the day

Data Source
Rounding
for Results
Excel
worksheet

Population

Measure
Formula
2N and 2 S
Numerator:
Supply Rooms Number of yes
of the
responses,
Surgicalmeaning one or
orthopedic
more
Unit
aromatherapy
inhalers are
available in the
2N and 2S
supply bins at
the time of
rounds
Denominator:
Number of
Rounding for
Results weekly
sessions
Numerator:
Weekly number
of inhalers in
each supply bin
Denominator:
Weekly par
levels for each
supply bin

Level of
Measurement
Nominal

Data Analysis
Target
Plan
Total percentage 100%
of weeks that
aromatherapy
inhalers were
available in the
2N and 2S
supply rooms

Ratio

Weekly
percentage of
number of
inhalers in bins
compared to par
levels
Range of
weekly
percentages

No target for
weekly
percentage
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Data Analysis Plan for Logic Model Outcomes
Variable
Type
Logic Model
Short Term
Outcome #3
(Independent)

Measure
Description
Verbal check-in
with the nurse
manager or
charge nurse to
validate
lavender
inhalers were
mentioned
during their
nurse leader
rounds with
patients

Data Source

Population

Rounding
for Results
Excel
worksheet

Surgicalorthopedic
unit nurse
leaders

Measure
Level of
Formula
Measurement
Numerator:
Nominal
Number of
Rounding for
Results sessions
in which
surgicalorthopedic unit
nurse leader
validates
mentioning
aromatherapy on
leader rounds
Denominator:
Number of
Rounding for
Results sessions

Data Analysis
Target
Plan
Total percentage 100%
of weeks that
surgicalorthopedic unit
nurse leader
validates
mentioning
aromatherapy on
leader rounds
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Data Analysis Plan for Logic Model Outcomes
Variable
Type
Logic Model
Medium
Term
Outcome #1
(Independent)

Logic Model
Medium

Measure
Description
Surgicalorthopedic unit
patients
screened for
aromatherapy
appropriateness/
lavender
contraindication

Surgicalorthopedic unit

Data Source

Population

Rounding
for Results
Excel
worksheet

Adult*
surgicalorthopedic
unit patients

Measure
Formula
Numerator:
Number of
cognitively
intact**
surgicalorthopedic unit
patients who
had
documentation
of pain during
the admission
and
documentation
of assessment
for lavender
contraindication
Denominator:
Number of
cognitively
intact**
surgicalorthopedic unit
patients who
had
documentation
of pain during
the admission

Level of
Measurement
Ratio

Data Analysis
Plan
Range of
weekly
percentages of
surgicalorthopedic unit
patients
cognitively
intact** patients
with
documentation
of pain during
the admission
and
documentation
of screening for
lavender
aromatherapy
contraindication

Target
Week 1: 20%
Week 2: 40%
Week 3: 60%
Week 4: 80%
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Data Analysis Plan for Logic Model Outcomes
Variable
Type
Term
Outcome #1
(Independent)
continued

Logic Model
Medium
Term
Outcome #2
(Independent)

Measure
Description
patients
screened for
aromatherapy
appropriateness/
lavender
contraindication
continued

Surgicalorthopedic unit
patients with
documentation
of no
contraindication
offered
lavender
aromatherapy
inhalers

Data Source

Population

Weekly
MedConnect
EMR Report

Adult*
surgicalorthopedic
unit patients

Rounding
for Results
Excel
worksheet

Adult*
surgicalorthopedic
unit patients

Measure
Formula
Numerator:
Weekly total
number of
surgicalorthopedic unit
patients who
had
documentation
of assessment
for lavender
contraindication
Denominator:
Weekly total of
surgicalorthopedic unit
discharges
Numerator:
Number of
cognitively
intact**
surgicalorthopedic unit
patients with
documentation
of pain during
admission,
documentation
of no lavender

Level of
Measurement
Ratio

Data Analysis
Plan
Range of
weekly
percentages of
surgicalorthopedic unit
patients with
documentation
of lavender
aromatherapy
contraindication
screening

Target

Ratio

Range of
weekly
percentages of
cognitively
intact**
surgicalorthopedic unit
patients with
documentation
of pain during
admission,
documentation

Week 1: 20%
Week 2: 40%
Week 3: 60%
Week 4: 80%

Week 1: 20%
Week 2: 40%
Week 3: 60%
Week 4: 80%
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Data Analysis Plan for Logic Model Outcomes
Variable
Type
Logic Model
Medium
Term
Outcome #2
(Independent)
Continued

Measure
Data Source
Description
Surgicalorthopedic unit
patients with
documentation
of no
contraindication
offered
lavender
aromatherapy
inhalers
continued

Weekly
MedConnect
EMR Report

Population

Adult*
surgicalorthopedic
unit patients

Measure
Level of
Formula
Measurement
contraindication,
and
documentation
of patient’s
response to
agree or not
agree to use
lavender
aromatherapy
Denominator:
Number of
cognitively
intact**
surgicalorthopedic unit
patients who
had pain during
the admission
Numerator:
Weekly total
number of
surgicalorthopedic unit
patients who
had
documentation
of no lavender
contraindication

Ratio

Data Analysis
Target
Plan
of no lavender
contraindication,
and
documentation
of patient’s
response to
agree or not
agree to use
lavender
aromatherapy

Range of
weekly
percentages of
surgicalorthopedic unit
patients who
had
documentation
of no lavender
contraindication

Week 1: 20%
Week 2: 40%
Week 3: 60%
Week 4: 80%
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Data Analysis Plan for Logic Model Outcomes
Variable
Measure
Type
Description
Logic Model
Medium
Term
Outcome #2
(Independent)
Continued

Data Source

Population

Measure
Formula
and
documentation
of patient’s
response to
agree or not
agree to use
lavender
aromatherapy
Denominator:
Weekly total of
surgicalorthopedic unit
discharges

Level of
Measurement

Data Analysis
Plan
and
documentation
of patient’s
response to
agree or not
agree to use
lavender
aromatherapy

Target
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Data Analysis Plan for Logic Model Outcomes
Variable
Type
Logic Model
Medium
Term
Outcome #3
(Independent)

Logic Model
Medium
Term
additional
data

Measure
Description
Surgicalorthopedic unit
patients who
demonstrated
correct use of
the lavender
inhalers

Percent of
screened
surgicalorthopedic unit
patients with
documentation

Data Source

Population

Rounding
for Results
Excel
worksheet

Adult*
surgicalorthopedic
unit patients

Weekly
MedConnect
EMR Report

Adult*
surgicalorthopedic
unit patients

Measure
Formula
Numerator:
Number of
cognitively
intact**
surgicalorthopedic unit
patients
observed to
correctly use the
lavender inhaler
Denominator:
Number of
cognitively
intact**
surgicalorthopedic unit
patients
observed to
correctly or
incorrectly use
the lavender
inhaler
Numerator:
Weekly total
number of
surgicalorthopedic unit
patients who

Level of
Measurement
Ratio

Data Analysis
Plan
Range of
weekly
percentages of
surgicalorthopedic unit
patients who
demonstrated
correct use of
the lavender
inhalers

Target

Ratio

Range of
weekly
percentages of
surgicalorthopedic unit
patients who

No target was set
for patient
agreement to use

100% of
surgicalorthopedic unit
patients will be
observed to selfadminister
lavender inhalers
by the end of the
fourth week of
the DNP student
Rounding for
Results sessions
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Data Analysis Plan for Logic Model Outcomes
Variable
Type
Logic Model
Medium
Term
additional
data
continued

Logic Model
Long Term
Outcome #1
(Dependent)
Same as
Project
Primary
Clinical
Question

Measure
Data Source
Description
of no lavender
aromatherapy
contraindication
who agreed to
use lavender
aromatherapy
inhaler.

Surgicalorthopedic unit
adult patient
pain
management
experience for
fiscal year (FY)
2019 quarters
one through

NRC Picker
database

Population

Adult*
surgicalorthopedic
unit inpatients
and adult
hospital
inpatients
completing
the NRC

Measure
Formula
had
documentation
of no lavender
contraindication
and
documentation
of patient’s
response to
agree to use
lavender
aromatherapy
Denominator:
The number of
patients
documented to
have responded
“no” to lavender
aromatherapy
contraindication
Percentage:
Numerator:
Number of
patients
answering the
question
“always”
Denominator:
Number of

Level of
Measurement

Data Analysis
Plan
had
documentation
of no lavender
contraindication
and
documentation
of patient’s
response to
agree or not
agree to use
lavender
aromatherapy

Target

Ratio

Mean, range of
quarterly
percentage
surgicalorthopedic unit
scores, hospital
overall scores
and Magnet

By the close of
the third quarter
of FY 2019,
surgicalorthopedic unit
scores equal or
above the
average score of
Magnet hospitals
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Data Analysis Plan for Logic Model Outcomes
Variable
Type
Outcome on
page 2
Logic Model
Long Term
Outcome #1
(Dependent)
continued

Measure
Description
three quarterly
percentage
scores and
Magnet hospital
comparison
percentiles for
the question
“During this
hospital stay,
how often did
hospital staff
talk with you
about how to
treat your
pain?”
Logic Model The number of
Long Term
surgicalOutcome #2
orthopedic unit
(Independent) patients
documented to
have no
contraindication
to lavender
aromatherapy
and who
received an
Logic Model offer of
Long Term
lavender
aromatherapy

Data Source

Population
picker
telephone
survey

Weekly
MedConnect
EMR Report

Adult*
surgicalorthopedic
unit patients
with
aromatherapy
documentation
in the
MedConnect
EMR database

Measure
Formula
patients
answering the
question

Level of
Measurement

Data Analysis
Plan
comparison
scores

Percentile:
Interval
Rank of unit and
hospital
percentage score
as compared to
Magnet
hospitals in the
NRC picker
database

Range of
quarterly
Magnet
percentiles for
surgicalorthopedic unit
and hospital
overall

Numerator:
The number of
patients
documented to
have responded
“no” to lavender
aromatherapy
contraindication
and documented
as verbally
responding
either “yes” or
“no” to an offer

Mean, range of
weekly
percentage
scores

Ratio

Target
in the NRC
Picker database
By the close of
the third quarter
of FY 2019,
surgicalorthopedic unit
scores will rank
at the Magnet
50th percentile in
the NRC Picker
database

100% of patients
for the two
weeks after the
DNP Rounding
for Results
sessions (weeks
five and six)
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Data Analysis Plan for Logic Model Outcomes
Variable
Type
Outcome #2
(Independent)
continued

Measure
Data Source
Description
reported on a
weekly basis for
two weeks after
the project

Population

The number of
lavender
inhalers
consumed on
the surgicalorthopedic unit
and in the
hospital overall

Surgicalorthopedic
unit and
Hospital units.

Supply
Chain
Database

Measure
Formula
of lavender
aromatherapy

Level of
Measurement

Denominator:
The number of
patients
documented to
have responded
“no” to lavender
aromatherapy
contraindication
Number of
Ratio
inhalers reported
used on the
surgicalorthopedic unit
each month.

Data Analysis
Plan

Target

Monthly report
of lavender
inhaler use by
the surgicalorthopedic unit
and the hospital
overall will be
compared with
the March and
April time
periods in the
MedConnect
EMR weekly
reports.

Monthly supply
chain
consumption
reports will
approximate the
same number of
patients using
lavender inhalers
as documented
in the March and
April
MedConnect
EMR weekly
reports.
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Data Analysis Plan for Logic Model Outcomes
Variable
Type
Logic Model
Long Term
additional
data

Measure
Description
Surgicalorthopedic unit
patients with
documentation
of no
contraindication
and agreement
to use lavender
aromatherapy
inhalers weekly
basis for two
weeks after the
project

Data Source

Population

Weekly
MedConnect
EMR Report

Adult*
surgicalorthopedic
unit patients

Measure
Formula
Numerator:
Weekly total
number of
surgicalorthopedic unit
patients who
had
documentation
of no lavender
contraindication
and
documentation
of patient’s
response to
agree to use
lavender
aromatherapy

Level of
Measurement
Ratio

Data Analysis
Plan
Range of
weekly
percentages of
surgicalorthopedic unit
patients who
had
documentation
of no lavender
contraindication
and
documentation
of patient’s
response to
agree or not
agree to use
lavender
aromatherapy

Denominator:
Denominator:
The number of
patients
documented to
have responded
“no” to lavender
aromatherapy
contraindication
*Adults are patients 18 years of age and older.
**Cognition was assessed by the nurse caring for the patient at the time of the Rounding for Results session.

Target
No target was set
for patient
agreement to use
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Appendix U
Project Primary Clinical Question Data Analysis
“Was the strategy of change agents effective in achieving implementation of nurse-directed lavender aromatherapy to improve pain
management experience in adult patients on a surgical-orthopedic unit of a community hospital?”
Interventions
Change
Agent
Strategy
Strategy #1
Three DNP
Student-led
Lunch &
Learns
Strategy #2
Four DNP
student-led
weekly
Rounding
for Results
sessions
Strategy #3
Two Pain
Champion
discussions

Session Attendance and Roles

Sessions
1
2
3
Total Per
Role
Sessions
1
2
3
4
Total All
Sessions
Sessions

RN
5
7
2
14

CNA
2
2
2
6

Total Attendee
7
9
5
21

Patients Per Session
21
19
18
20
78
Pain
Champions

1

4

2

4

Outcome: Bundle of All Three Strategies

Outcome: Met

US
0
0
1
1

Pain
Champion
Leaders
4
3

Total
Attendees Per
Session
8
7

Descriptive Statistics

Strategy
Complete

Attendee number per session range:
5-9
Attendee mean per session: 7
Range among roles: 14 Registered
Nurses, 6 Certified Nursing
Assistants, and 1 Unit Secretary
Mean = 20 patients per session
Range = 18-21 patients per session

Yes

Mean = 7.5
Range = 7-8

Yes

Yes

Note: Most pain champions and
pain champion leaders attended both
sessions.
Met
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Project Primary Clinical Question Data Analysis
“Was the strategy of change agents effective in achieving implementation of nurse-directed lavender aromatherapy to improve pain
management experience in adult patients on a surgical-orthopedic unit of a community hospital?”
After the intervention, the Surgical-orthopedic Unit exceeded the average score and 50th percentile of Magnet hospitals in the NRC
Picker database for the question “During this hospital stay, how often did hospital staff talk with you about how to treat your pain?”
Scores ranged from 52.2 in FY 19 Quarter 1 to 72.2 in FY 19 Quarter 3.
Percentiles ranged from 12th in FY 19 Quarter 1 to 78th in FY 19 Quarter 3.
Unit/Entity
FY 19 Quarter 1
FY 19 Quarter 2
FY 19 Quarter 3
Total FY 19 Quarters 1-3
Combined
Positive PR
n Size Positive PR n Size
Positive PR n Size Positive PR
n Size
Surgical-orthopedic
Unit
Hospital Overall

52.2

12

46

63.0µ

43

27

72.2

78

36

61.5

40

109

59.3

31

189

66.3

56

166

64.1

46

166

62.9

44

525

NRC Picker Magnet
64.8
50
64.9
50
64.7
50
64.7
Hospital Benchmark
µ= sample size below 30 patients and not adequate for statistical reliability as noted in the NRC Picker Database.

50
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Appendix V
Project Aims Data Analysis
Aim #1 To increase the surgical-orthopedic unit patient HCAHPS pain management experience score to equal or above the Magnet
average of hospitals in the NRC Picker database by the end of the third quarter of FY 2019 for the question “During this hospital
stay, how often did hospital staff talk with you about how to treat your pain?”
Outcome: Met
After the intervention, the Surgical-orthopedic Unit exceeded the average score and 50th percentile of Magnet hospitals in the NRC
Picker database.
Scores ranged from 52.2 in FY 19 Quarter 1 to 72.2 in FY 19 Quarter 3.
Percentiles ranged from 12th in FY 19 Quarter 1 to 78th in FY 19 Quarter 3.
Unit/Entity
FY 19 Quarter 1
FY 19 Quarter 2
FY 19 Quarter 3
Total FY 19 Quarters 1-3
Combined
Positive
PR
n
Positive
PR n Size Positive
PR
n Size Positive
PR n Size
Size
Surgical52.2
12
46
63.0µ
43
27
72.2
78
36
61.5
40
109
orthopedic Unit
Hospital
59.3
31
189
66.3
56
166
64.1
46
166
62.9
44
525
Overall
NRC Picker
64.8
50
64.9
50
64.7
50
64.7
50
Magnet
Hospital
Benchmark
µ= sample size below 30 patients and not adequate for statistical reliability as noted in the NRC Picker Database.
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Project Aims Data Analysis
Aim #2 To achieve a consistent practice of 100 % of appropriate patients being offered lavender aromatherapy by the end of the
third quarter of FY 2019.
Aim #2a Outcome: Not Met
Based on the weekly MedConnect EMR data below, 100% of surgical-orthopedic unit patients documented to have no
contraindication to lavender aromatherapy received an offer of lavender aromatherapy reported on weeks 1, 2, 4, 5, and 6. The goal
was not met on week 3. The range of percentages were 91.7% to 100% and the mean was 97.1%.
Cerner MedConnect Electronic Medical Record Aromatherapy Data
Population
Week/Total
Patient
Record
Data
Documentation
Outcomes

Surgical-Orthopedic Surgical Unit

All Hospital Inpatients

1
32
0

2
40
0

3
45
0

4
32
0

5
40
0

6
31
0

Total
220
0

1
963
0

2
1005
0

3
1046
0

4
1098
0

5
1079
0

6
1031
0

Total
6222
0

25.0
%
N=
8/32

10.0
%
N=
4/40

3.1
%
N=
1/32

17.5
%
N=
7/40

6.5
%
N=
2/31

0.4%

1.3%

0.5%

1.3%

0.8%

0.9%

100.0
%
N=
8/8

100.0
%
N=
4/4

100.0
%
N=
1/1

100.0
%
N=
7/7

100.0
%
N=
2/2

100.0
%
N=
1/1

100.0
%
N=
7/7

100.0
%
N=
2/2

N=
14/
1079
100.0
%
N=
14/
14
100.0
%
N=
14/
14

N=
8/
1031
100.0
%
N=
8/8

100.0
%
N=
4/4

N=
14/
1046
92.9
%
N=
13/
14
92.9
%
N=
13/
14

N=
6/
1098
100.0
%
N=
6/6

100.0
%
N=
8/8

N=
10/
963
100.0
%
N=
10/
10
100.0
%
N=
10/
10

N=
4/
1005
100.0
%
N=
4/4

Percent of patients with
documentation of
agreement to use lavender
aromatherapy****

15.5
%
N=
34/
220
97.1
%
N=
33/
34
97.1
%
N=
33/
34

1.3%

Percent of patients with
lavender aromatherapy
offer documented ***

26.7
%
N=
12/
45
91.7
%
N=
11/
12
91.7
%
N=
11/
12

N=
56/
6222
98.2
%
N=
55/
56
98.2
%
N=
55/
56

Inpatient Records Queried
Inpatients with
Contraindication to
Lavender Documented
Patients with lavender
aromatherapy
contraindication screening
documented*

100.0
%
N=
4/4

100.0
%
N=
6/6

100.0
%
N=
8/8

*Numerator is number of adult (age 18 or older) orthopedic surgical unit patients with Lavender Contraindication/Reaction field documented as “Yes” or “No” and denominator is number of adult
(age 18 or older) orthopedic surgical unit patients.
** Numerator is number of adult (age 18 or older) orthopedic surgical unit patients with Lavender Contraindication/Reaction field documented as “Yes” and denominator is number of adult (age 18
or older) orthopedic surgical unit patients with Lavender Contraindication/Reaction field documented as “Yes” or “No.”
*** Numerator is number of adult (age 18 or older) orthopedic surgical unit patients with Lavender Contraindication/Reaction field documented as “No” and the Verbal Agreement field documented
as “Yes” or “No” and denominator is number of adult (age 18 or older) orthopedic surgical unit patients with Lavender Contraindication/Reaction field documented as “No.”
**** Numerator is number of adult (age 18 or older) orthopedic surgical unit patients with Lavender Contraindication/Reaction field documented as “No” and the Verbal Agreement field
documented as “Yes” and denominator is number of adult (age 18 or older) orthopedic surgical unit patients with Lavender Contraindication/Reaction field documented as “No.”

CHANGE AGENT IMPACT ON PAIN THROUGH AROMATHERAPY

136

Project Aims Data Analysis
Aim #2b Outcome: Not Met
Based on Rounding for Results weekly observation sessions, 100% of surgical-orthopedic unit patients documented to have no
contraindication to lavender aromatherapy received an offer of lavender aromatherapy on three of four weeks. The goal was not met
on week 3. The range of percentages were 66.7% to 100% and the mean was 88.89%.
Patients/
Description
Week 1 Week 2 Week 3 Week 4 Total
Outcomes
Patients/ Records Total Patients Rounded
21
19
18
20
78
Observed
Patients Not Appropriate for Aromatherapy Screening Due
9
7
12
12
40
to Cognitive Impairment or No Pain During Hospitalization
Patients with Documentation of Contraindication to
0
0
0*
0
0
Lavender
Documentation
Goal
20%
40%
60%
80%
N/A
Outcomes
Appropriate patients** with lavender aromatherapy
16.7%
16.7%
50.0% 25.0% 23.7%
contraindication screening documented.
N= 2/12 N= 2/12 N=3/6 N=2/8 N=9/38
Goal
100%
100%
100%
100%
100%
Screened patients with lavender aromatherapy education
100%
100%
66.7%
100% 88.89%
documented.
N= 2/2 N= 2/2 N= 2/3 N=2/2
N=8/9
Screened patients with lavender aromatherapy offer
100%
100%
66.7%
100% 88.39%
documented.
N= 2/2 N= 2/2 N= 2/3 N=2/2
N=8/9
Observation
Goal
100%
100%
100%
100%
100%
Outcome
Patients with documented agreement to use lavender
50.0%
50.0%
50.0%
0.0%
37.5%
aromatherapy demonstrating correct use of lavender inhaler.
N=1/2
N=1/2
N=1/2 N=0/2 N=3/8
*One patient reported intolerance to lavender, but documentation was not completed.
** Patients without cognitive impairment and with reported pain during the hospital stay.
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Appendix W
Logic Model Outcomes Data Analysis
Variable Type Outcome Description

Measure

Logic Model
Short Term
Outcome #1A
(Independent)

Community Hospital Aromatherapy SiTEL Completion by Unit
Unit
N
1E
30
1W
31
2E
19
2 N/2S
26 (24 RN, 2 CNA)
2W
14
Cardiac Cath Lab
21
ICU/CCU
39
Nursing Administration
5
Nursing Education
3
Orientation
1
Peri-Operative
48
Psychiatry
1
Resource Management & RN Float Pool
43
Rehab-Stroke Center
2
Women's Services
46
Total
329
Community Hospital Aromatherapy SiTEL Completion by Role
Role
N
Clinical Nurses (Direct Care)
225
Certified Nursing Assistants
32
Nurse Leaders
18
Technicians
12
Non-Direct Care Nurses
11
Unit Secretary
10

Nurse PCs, surgicalorthopedic unit clinical
nurses, and nurse PCs
articulated: Lavender
aromatherapy benefits,
patient assessment protocol
and patient education key
points as indicated by
successful completion of the
SiTEL Aromatherapy
module

Target/
Outcome
Target=100%
of surgicalorthopedic
unit nurses
Outcome=
24/24
surgicalorthopedic
unit nurses
successfully
completed
SiTEL
module (score
of > 80%).
Goal Met

No target for
all associates
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Logic Model Outcomes Data Analysis
Variable Type Outcome Description

Measure

Logic Model
Short Term
Outcome #1A
(Independent)
continued

Community Hospital Aromatherapy SiTEL Completion by Role
continued
Role
N
PAs/SAs
8
Other (Center Hall Coordinator/OR
5
Transport)
APRN
3
RN-Educator
2
LPN
2
Physician
1
Total
329
Nurses who
Week
Total
provide verbal
1
2
3
4
intent to offer
100%
100%
100%
83%
96%
lavender
N=
N=
N=
N=
N=
5/5
7/7
5/5
5/6
22/23

Logic Model
Short Term
Outcome #1B
(Independent)

Surgical-orthopedic unit
clinical nurses, including
nurse PCs, articulated intent
to offer lavender inhalers to
patients at each Rounding
for Results session

Logic Model
Short Term
Outcome #1C
(Independent)

At each Rounding for
Results session, surgicalorthopedic unit nurses’
skills to appropriately use
and teach patients to use
lavender inhalers was
evaluated by observation of
patients use of lavender
inhalers

Patients with
documented
agreement to use
lavender
aromatherapy
demonstrating
correct use of
lavender inhaler

Target/
Outcome

Week

Total

1

2

3

4

50%
N=
1/2

50%
N=
1/2

50%
N=
1/2

0%
N=
0/2

37.5%
N=
3/8

Target=
100%
Outcome=
Not Met
Overall (was
met three out
of four
weeks)
Target=100%
Outcome=
Not met
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Logic Model Outcomes Data Analysis
Variable Type Outcome Description
Logic Model
Short Term
Outcome #2
(Independent)

Measure

At each Rounding for
Inhaler Adequacy
Results session, the par
levels for lavender inhalers
that were established by the Inhalers Available in
Bin (YES, NO)
surgical-orthopedic unit
nurse leaders were
compared with the adequacy
and number of lavender
inhalers observed
Inhaler Count

Inhaler Count North
Supply Room
Inhaler Par North
Supply Room
% Inhaler Count to
Par North Supply
Room
Inhaler Count
South Supply Room
Inhaler Par South
Supply Room
% Inhaler Count to
Par South Supply
Room

Week

Total

1

2

3

4

YES

YES

YES

YES

Week

4/4 YES

Total

1

2

3

4

6

10

6

8

30

5

10

10

10

35

120%

100%

60%

80%

86%

3

9

6

8

26

5

10

10

10

35

60%

90%

60%

80%

74%

Target/
Outcome
Target=100%
of weeks
inhalers will
be available
in the supply
room bins
Outcome=
Met 4/4
weeks
No target for
percentage
Nurse leaders
increased par
levels on
week 2.
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Logic Model Outcomes Data Analysis
Variable Type Outcome Description

Measure

Logic Model
Short Term
Outcome #3
(Independent)

Nurse Leader Rounding

At each Rounding for
Results session, orthopedic
surgical unit nurse leaders,
including the nurse manager
or charge nurse on duty,
validated lavender inhalers
were mentioned during their
nurse leader rounds with
patients

Nurse leader validates
mentioning
aromatherapy on leader
rounds
(YES, NO)

Week
1
YES

2
YES

3
YES

Total
4
YES

4/4 YES

Target/
Outcome
Target=
100%
Outcome=
Met 4/4
weeks
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Logic Model Outcomes Data Analysis
Variable Type Outcome Description
Logic Model
Medium Term
Outcome #1
(Independent)

Surgical-orthopedic unit
patients screened for
aromatherapy
appropriateness/lavender
contraindication

Measure
Week

Total

Patient Screening
Based on Rounding for
Results observation:
Percent of appropriate
patients with lavender
aromatherapy
contraindication
screening documented.
Based on weekly
MedConnect EMR
reports: Percent of
patients with lavender
aromatherapy
contraindication
screening documented
on Surgical-Orthopedic
unit

1
16.7
%
N=
2/12

2
16.7
%
N=
2/12

3
50.0
%
N=
3/6

4
25.0
%
N=
2/8

N/A
23.7
%
N=
9/38

25.0
%
N=
8/32

10.0
%
N=
4/40

26.7
%
N=
12/
45

3.1
%
N=
1/32

16.7
%
N=
25/149

Target/
Outcome
Target=
Week 1: 20%
Week 2: 40%
Week 3: 60%
Week 4: 80%
Outcome=
Not met on
any of the
four weeks
Target=
Week 1: 20%
Week 2: 40%
Week 3: 60%
Week 4: 80%
Outcome=
Met on week
1
Not met
weeks 2-4
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Logic Model Outcomes Data Analysis
Variable Type Outcome Description

Measure

Logic Model
Medium Term
Outcome #2
(Independent)

Lavender
Aromatherapy Offer

Logic Model
Medium Term
Outcome #3
(Independent)

Surgical-orthopedic unit
patients with documentation
of no contraindication
offered lavender
aromatherapy inhalers

Surgical-orthopedic unit
patients demonstrated
correct use of the lavender
inhalers during Rounding
for Results sessions

Week

Total

1

2

3

4

Based on Rounding for
Results observation:
Lavender aromatherapy
offer and education
documented if no
contraindication.
Based on Weekly
MedConnect EMR
reports: Percent of
screened patients with
lavender aromatherapy
contraindication
documented as “No”
and lavender
aromatherapy inhaler
offer documented as
“Yes” or “No.”
Patient Use of Lavender
Inhaler

100
%
N=
2/2

100
%
N=
2/2

66.67
%
N=
2/3

100
%
N=
2/2

88.89
%
N=
8/9

100
%
N=
8/8

100
%
N=
4/4

92
%
N=
11/12

100
%
N=
1/1

96
%
N=
24/25

1

2

3

4

Based on Rounding for
Results observation:
Patient demonstrates
correct use of lavender
inhaler.

50%
N=
1/2

50%
N=
1/2

50%
N=
1/2

0%
N=
0/2

Week

Total
37.5%
N=
3/8

Target/
Outcome
Target=
Week 1: 20%
Week 2: 40%
Week 3: 60%
Week 4: 80%
Outcome=
Met on all
four weeks

Target =
100% by
week 4
Outcome=
Not met
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Logic Model Outcomes Data Analysis
Variable Type Outcome Description

Measure

Logic Model
Medium Term
Additional
Data

Patient Agreement to
Use Lavender Inhalers

Percent of screened
surgical-orthopedic unit
patients with documentation
of no lavender
aromatherapy
contraindication who agreed
to use lavender
aromatherapy inhaler.

Week

Total

1

2

3

4

100%
N=
8/8

100%
N=
4/4

92%
N=
11/12

100%
N=
1/1

96%
N=
24/25

Target/
Outcome
No target was
set for patient
agreement to
use
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Logic Model Outcomes Data Analysis
Variable Type Outcome Description
Logic Model
Long Term
Outcome #1
(Dependent)
Same as
Project
Primary
Clinical
Question
Outcome on
page 2

Surgical-orthopedic unit
adult patient pain
management experience for
fiscal year (FY) 2019
quarters one through three
quarterly percentage scores
and Magnet hospital
comparison percentiles for
the question “During this
hospital stay, how often did
hospital staff talk with you
about how to treat your
pain?”

Measure

Magnet Average

1
64.8

FY 2019 Quarter
2
3
1-3 Combined
64.9
64.7
64.7

Number of Patient
Responses

46

27

36

109

Percentage

52.2

63.0µ

72.2

61.5

Percentile

12th

43rd

78th

40th

Target/
Outcome
Target =
By the close
of the third
quarter of FY
2019,
surgicalorthopedic
unit scores
equal or
above the
average score
and 50th
percentile of
Magnet
hospitals in
the NRC
Picker
database
Outcome=
Met
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Logic Model Outcomes Data Analysis
Variable Type Outcome Description

Measure

Logic Model
Long Term
Outcome #2
(Independent)
Similar to
Aim #2
Outcome on
pages 3 and 4

Aromatherapy Offer
Post Implementation

The number of surgicalorthopedic unit patients
documented to have no
contraindication to lavender
aromatherapy and who
received an offer of
lavender aromatherapy
reported on a weekly basis
for two weeks after the
project

Based on hospital supply
chain, the number of
lavender inhalers consumed
on the surgical-orthopedic
unit and in the hospital
overall

Based on Weekly
MedConnect EMR
reports: Percent of
surgical-orthopedic unit
screened patients with
lavender aromatherapy
contraindication
documented as “No”
and lavender
aromatherapy inhaler
offer documented as
“Yes” or “No.”
Lavender Inhaler
Consumption
Surgical-orthopedic
Unit
All Hospital Inpatient
Units (nine units
including surgicalorthopedic unit)
Surgical Unit Percent
of Overall Lavender
Inhaler Consumption

Week
5
100%
N=
7/7

6
100%
N=
2/2

Mean of
Weeks
5&6
100%
N=
9

Feb.
69

Month
March
75

Total
April
79

223

207

212

250

669

33%

35%

32%

33%

Target/
Outcome
Target= 100%
of patients in
the two weeks
following the
four
Rounding for
Results
sessions
(weeks five
and six)
Target = Met

No Target set
for lavender
inhaler
consumption.
Consumption
quantity does
not match the
number of
EMRdocumented
patient uses.
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Logic Model Outcomes Data Analysis
Variable Type Outcome Description

Measure

Long Term
additional
data

Patient Agreement to
Use Lavender Inhalers

Surgical-orthopedic unit
patients with documentation
of no contraindication and
agreement to use lavender
aromatherapy inhalers
weekly basis for two weeks
after the project

Based on weekly
MedConnect EMR
reports: Based on
Weekly MedConnect
EMR reports: Percent
of surgical-orthopedic
unit screened patients
with lavender
aromatherapy
contraindication
documented as “No”
and lavender
aromatherapy inhaler
offer documented as
“Yes.”

Week
5

6

100%
N=
7/7

100%
N=
2/2

Mean of
Weeks
5&6
100%
N=
9

Target/
Outcome
No target was
set for patient
agreement to
use
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Appendix X

Percentage of Surgical-Orthopedic Unit vs. All Inpatients with
Documentation of Assessment for Contraindication to Aromatherapy
30%

26.67%
25%

25.00%

Percentage of Patients

20%
17.50%
Surgical Orthopedic Surgical Unit
All Inpatient Units

15%

10%

10.00%

6.45%
5%
3.13%
1.34%

1.04%
0%
1

2

3

4

Week

1.30%

0.55%

0.40%

5

0.78%
6
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